Subject Index—Volume 92

No. 1, July 1, pp. 1–206
No. 2, July 15, pp. 207–452
No. 3, August 1, pp. 453–712
No. 4, August 15, pp. 713–968
No. 4, August 15, Supplement, pp. 969–1058
No. 5, September 1, pp. 1059–1348
No. 6, September 15, pp. 1349–1656
No. 6, September 15, Supplement, pp. 1657–1744
No. 7, October 1, pp. 1745–1998
No. 8, October 15, pp. 1999–2234
No. 9, November 1, pp. 2235–2492
No. 10, November 15, pp. 2493–2732
No. 11, December 1, pp. 2733–2964
No. 12, December 15, pp. 2965–3170

A

ABI-007, intraarterial infusion of, for squamous cell carcinoma, 2592
ACE inhibitors, in cancer prevention, 2462
Acidosis, lactic, in hematologic cancers, 2237
Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
Activity and exercise
  breast cancer risk and, 1638
  in fatigue management, 988, 1689, 1699
Acute leukemia. *See* Leukemia
Adenomatous polyposis coli, hepatocellular carcinoma in, *APC* inactivation and, 332
Adolescents. *See also* Children
  bone tumors in, rehabilitation for, 1013
Adrenal tumors, menin in, 1393
Adrenocortical cancer
  clinical outcome in, 1113
  1-1,dichlorodiphenildichloroethane in, prognosis and, 1385
Adriamycin. *See* Doxorubicin
Advance directives, predictors of survival after CPR and, 1905
African Americans
  breast cancer hormone receptor status in, tumor characteristics and, 37
  comorbid illness and complications in hysterectomy for endometrial carcinoma in, 950
  mammography in, recommendations for, 1299
  prostate cancer in
    genetic polymorphisms affecting androgen biosynthesis and, 1130
    quality of life and, 1451
    screening for, 2673
AIDS. *See* Human immunodeficiency virus infection
Alanine aminotransferase, as prognostic factor, for hepatocellular carcinoma treated with percutaneous ethanol injection, 126
Alcohol use/abuse
  breast cancer risk and, familial factors affecting, 240
  in unresectable lung cancer, 2609
Alkylating agents, gemcitabine as modulating agent for, 194
Allogeneic blood transfusion, in esophageal cancer, prognosis and, 1913
Alpha-fetoprotein, as prognostic factor, for hepatocellular carcinoma treated with percutaneous ethanol injection, 126
Alternative therapies, for fatigue, 1714
Alveolar rhabdomyosarcoma, neonatal, with skin and brain metastases, 1613
American Indians, breast cancer hormone receptor status in, tumor characteristics and, 37
Amifostine
  with cisplatin, for breast cancer, 2517
  twice-daily, for refractory pediatric cancers, 914, 3170 (erratum)
Amputation, rehabilitation after, 1013
Amyloid A, in renal cell carcinoma, prognosis and, 1072
AN-238, for ovarian cancer, 1168
Anal cancer
  inguinal node metastases in, management of, 77
  intraarterial polyoxyethylated castor oil–free paclitaxel for, 2592
Analgesics. *See* Pain
Anal gland cancer, 2045
Anastrozole
  for breast cancer, vs. tamoxifen, 2247
  for prostate cancer, 2095
Androgen biosynthesis, genetic polymorphisms affecting, prostate cancer risk and, 1130
Androgen blockade, for prostate cancer
  mortality trends and, 2309
  pamidronate after, 1444
Androgen receptor CAG repeat, in endometrial cancer, in Israeli Jews, 1190
Androgen receptor gene, short tandem repeat polymorphism linkage to, in prostate cancer, 2603

Androgen receptor gene CAG repeat polymorphism, in prostate cancer, in Australia, 941
Anemia, fatigue and, 1678, 1684, 1719
Angiogenesis
in breast cancer
monocyte chemoattractant protein-1 in, 1085
tumor progression and, 249
in colorectal cancer, angiopoietin-1/2 and, 1138
in endometrial cancer, 2569
in head and neck cancer, thalidomide inhibition of, 2364
in leiomyosarcoma, vitaxin inhibition of, 1347 (letter)
in nonsmall cell lung cancer, prognosis and, 2648
in oligodendrogliomas, hypoxia-inducible factor-1α and, 165
in pancreatic cancer, 1788
vascular endothelial growth factor and
in endometrial cancer, 2569
in esophageal cancer, 663
in head and neck cancer, nodal metastasis and, 556
inhibitors of, for acute myelogenous leukemia, 1059
in nonsmall cell lung cancer, 2628
in pancreatic cancer, 488, 1788
Angiogenesis inhibitors
thalidomide as, in head and neck cancer, 2364
vitaxin as, in leiomyosarcoma, 1347 (letter)
Angiopoietin-1/2, colorectal cancer and, 1138
Angiosarcoma, after radiotherapy, for breast cancer, 172
Angiotensin-converting enzyme inhibitors, in cancer prevention, 2462
Annexin II, overexpression of, stromal tenascin-C overexpression and, in colorectal cancer, 1419
Anorexia, neuropeptide Y, leptin and cholecystokinin 8 and, 629
Anthracyclines, for acute myelogenous leukemia, 1059
Antiandrogen therapy, for prostate cancer, pamidronate after, 1444
Antiangiogenesis agents
thalidomide as, in head and neck cancer, 2364
vitaxin as, in leiomyosarcoma, 1347 (letter)
Anti-CD33 monoclonal antibodies, for acute myelogenous leukemia, 1059
Antidepressants, for fatigue, 1714
Antioxidants, ovarian cancer risk and, 2318
Antiretroviral therapy, chemotherapy and, for testicular germ cell tumors in HIV infection, 1460
Anxiety disorders, in unresectable lung cancer, 2609
Aortic lymphadenectomy, in elderly, 2562
APC
founder mutations in, in Australian Ashkenazi Jews, 440
inactivation of, hepatocellular carcinoma in familial adenomatous polyposis coli and, 332
Apoptosis
BCL2 and, in pancreatic cancer, 1122
in hepatocarcinogenesis, 2733
in HHV-8–associated malignancies, p53 and LANA in, 3076
in mature vs. immature mediastinal teratomas, 1798
2-methoxyestradiol-induced capsase activation and, in gastric cancer, 500
in nonsmall cell lung cancer, γ-glutamyl cysteine synthetase in, 2911
in ovarian cancer, cyclin-dependent kinase inhibitors and, 1177
in prostate cancer, capsases in priming for, 2297
in pulmonary artery sarcoma, 1237
survivin and, 271
Appendiceal carcinoids, incidence trends and risk factors for, 2204
Ara-C. *See* Cytarabine
Arm, lymphedema of. *See* Lymphedema
Aromatase inhibitors, for prostate cancer, 2095
Ashkenazi Jews
BRCA1/2 and *APC* founder mutations in, frequency of, in Australia, 440
BRCA1/2 founder mutations in, genetic testing for, educational materials on, 932
Asian-Americans, breast cancer hormone receptor status in, tumor characteristics and, 37
Aspartate aminotransferase, as prognostic factor, for hepatocellular carcinoma treated with percutaneous ethanol injection, 126
Astroglioma, MIB-1 labeling index for, prognosis and, 2720
Ataxia-telangiectasia, *ATM* mutations in, breast cancer and, 479
Australia
Ashkenazi Jews in, frequency of *BRCA1/2* and *APC* founder mutations in, 440
prostate cancer in, androgen receptor gene CAG repeat polymorphism in, 941
Axillary node dissection, in breast cancer, lymphedema and, 1368
Azoospermia, postchemotherapy, testicular sperm extraction with intracytoplasmic sperm injection in, 1632
AZT, chemotherapy and, for testicular germ cell tumors in HIV infection, 1460

B

Bacteremia, risk factors for, in children with febrile neutropenia, 909
Bandages, for lymphedema, 980
Basal cell carcinoma
likelihood of participation in preventive behaviors for, 1315
truncal, susceptibility to, 354
Basic fibroblast growth factor, in pancreatic cancer, 1788
Bax, in pulmonary artery sarcoma, 1237
BAY 59-8862 (taxane analog), for glioma, 3085
B-cell chronic lymphocytic leukemia, prognosis and, 713
BCL2, in pancreatic cancer metastasis, 1122
Bcl-2, in pulmonary artery sarcoma, 1237
Bcl-2 inhibitors, for acute myelogenous leukemia, 1059
Benzopyrones, for lymphedema, 980

Benzydamine hydrochloride, prophylactic, for radiation-induced oral mucositis, 875
Biopsy
prostate, suspicious for malignancy, predictive value of, 524
sentinel node
in breast cancer
after preoperative chemotherapy, 1080
treatment implications of, 1769
in papillary thyroid cancer, 2868
Blacks. *See* African Americans
Bladder cancer
cyclooxygenase-2 in, tumor invasiveness and survival and, 188
FGFR3 in, thanatophoric dysplasia mutations in, 2555
follow-up in, microsatellite analysis vs. cystoscopy in, 768
gemcitabine and paclitaxel for, 2993
Ku heterodimer in, 2484
monitoring in
DNA/cytokeratin flow cytometry in, 2811
serial urinary tumor markers in, 2811, 2820
UBC antigen ELISA test in, 2811, 2820
serum soluble Fas ligand in, 287
thymidylate synthase in, prognosis and, 510
transforming growth factor-β_1 in, prognosis and, 1475, 2985
urethra-sparing cystectomy for, in women, 1864
Bleomycin, for primary hepatic lymphoma, 2023
Blood transfusion, allogeneic, in esophageal cancer, prognosis and, 1913
Body mass index, in younger women with breast cancer, prognosis and, 720
Bone-anchored craniofacial prostheses, patient satisfaction with, 3045
Bone marrow metastasis
in breast cancer, maspin as marker for, 2030
occult, in breast cancer, prognosis and, 46
Bone marrow transplantation
for acute myelogenous leukemia, 1059
illness intrusiveness after, 3147
osteoporosis after, pathogenesis of, 2419
pediatric, chemotherapy-induced stomatitis in, TRAUMEEL S for, 684
rehabilitation after, 998
Bone metastasis
in breast cancer, surgery for, 257
in prostate cancer
predictors of occult spinal cord compression in, 303
urinary calcium excretion in monitoring of, 1468
receptor activator of nuclear factor-*K*B ligand and, 460
rehabilitation and, 1020
Bone tumors. *See also specific types*
amputation for, rehabilitation for, 1013
ifosfamide with radiotherapy for, toxicity of, 1550
limb salvage in, rehabilitation for, 1013
osteoprotegerin for, 460
Brachytherapy. *See also* Radiation therapy
endobronchial, for tracheobronchial tumors, massive hemoptysis after, 2623
for prostate cancer
long-term results of, 2084
quality of life after, 1451
Brain metastasis
in lung cancer, after high-dose preoperative chemoradiotherapy, 160
in neonatal alveolar rhabdomyosarcoma, 1613
rehabilitation for, 1029
in rhabdomyosarcoma, routine brain scans for at diagnosis, 121
Brain tumors
epidemiology of, in Germany, 3155
glioma
C-methionine PET in, prognosis and, 1541
liposomal doxorubicin for, 1936
radiotherapy for, with carmustine with/without interferon-α, 420
taxane analog BAY 59-8862 for, 3085
lipid-associated sialoprotein in cerebrospinal fluid and, 856
MIB-1 labeling index for, prognosis and, 2720
pediatric
increasing incidence of, in England, 1967
medical and neurocognitive late effects in, 2709
rare *HRAS1* alleles and, 2920
rehabilitation for, 1029
BRCA1
founder mutations in, in Ashkenazi Jews
in Australia, 440
genetic testing for, educational materials for, 440
prognostic value of, in Japan, 54
BRCA1/2, founder mutations in, in Ashkenazi Jews, in Australia, 440
BRCA2
founder mutations in, in Ashkenazi Jews
in Australia, 440
genetic testing for, educational materials for, 440
in ovarian cancer, 787
Breast
fibroadenoma with atypia of, breast cancer risk and, 30
metastasis to, 2259
MRI of, with 3D fat suppression, 471
Breast cancer
ACE inhibitor protective effect for, 2462
advanced, conditional median survival in, 2211
alcohol-related risk of, familial factors affecting, 240
anastrozole vs. tamoxifen for, 2247
angiogenesis in, tumor progression and, 249
ATM missense mutations in, 479
axillary node dissection in, lymphedema and, 1368
bone metastasis in, receptor activator of nuclear factor-*K*B ligand and, 460
BRCA1/2 and
founder mutations in, in Ashkenazi Jews
in Australia, 440

genetic testing for, educational materials for, 440
prognostic value of, in Japan, 54
breast conservation therapy for, in elderly, 1092
cathepsin D in, prognosis and, 2957
chemotherapy response in, ^{99m}-Tc-MIBI scintigraphy in prediction of, 232
cisplatin with amifostine for, 2517
cumulative incidence of, 2220
ductal in situ, mastectomy for, vs. breast-conserving therapy, 23
early-stage, adjuvant therapy for, 1354
estrogen/progesterone status in, race/ethnicity and, 37
HER-2/*neu* DNA amplification in, 2965
hereditary, preventive strategies for, attitudes toward in English, French and Canadian women, 959
inflammatory, paclitaxel for, 1775
lobular in situ, E-cadherin in, risk of subsequent cancer and, 738
lymphedema in
axillary node dissection and, 1368
management of, 980
risk factors for, 1783
after sentinel lymphadenectomy, 748
at 20-year follow-up, 1368
mitoxantrone with cyclophosphamide for, 2508
monocyte chemoattractant protein-1 in, 1085
MRI in, with 3D fat suppression, 471
occult bone marrow metastases in, prognosis and, 46
in older women, chemotherapy for, 730
radiofrequency ablation for, 2036
radiotherapy for
soft tissue sarcoma after, 172
thyroid cancer after, 1411
risk of
with fibroadenoma with atypia, 30
physical activity and, 1638
screening for, targeted subpopulations for, 1299
sentinel lymphadenectomy for, lymphedema after, 748
sentinel node biopsy in
positive, treatment implications of, 1769
after preoperative chemotherapy, 1080
sentinel node micrometastases in, 1378
skeletal metastasis in, surgery for, 257
stromelysin-3 and, prognosis and, 2957
tamoxifen-treated, risk of endometrial polyps in, 1151
taxane-refractory/failing, capecitabine for, 1759
urokinase in, prognosis and, 2957
vinorelbine for, in salvage therapy, 2267
in women with thyroid cancer, 225
in younger women
body mass index and prognosis in, 720
poor prognosis in, 2523
surgery and chemotherapy for, quality of life and, 1288
Bronchioloalveolar cancer. *See also* Lung cancer
DNA mismatch repair genes in, 2898

C

CA-125-II, in ovarian cancer, 2837
Cachexia
cytokines and, 1684
fatigue and, 1678, 1684
muscle wasting in, 1669
Calcium, urinary, in monitoring of bone metastases, in prostate cancer, 1468
Calpain, in merlin proteolysis, in meningiomas, 2662
Canada, attitudes toward preventive strategies for hereditary breast/ovarian cancer in, 959
Cancer
ACE inhibitor protective effect for, 2462
advanced, conditional median survival in, 2211
Cancer cachexia
cytokines and, 1684
fatigue and, 1678, 1684
muscle wasting in, 1669
Cancer pain
fatigue and, 1678, 1684
fentanyl for, conversion from IV to transdermal administration of, 3056
intravenous methadone for, 1919
management of
in advanced cancer, 1049
conversion from IV to transdermal fentanyl in, 3056
Cancer rehabilitation
in advanced disease, 1039
in amputation, 1013
after bone marrow transplantation, 998
bone metastasis and, 1020
for central nervous system tumors, 1029
fatigue and, 988. *See also* Fatigue
future directions in, 975
history of, 970
integration of into medical care, 1055
for limb salvage patients, 1013
lymphedema and, 980
palliative care and, 1049
sexuality, 1008
Cancer-related fatigue. *See* Fatigue
Cancer survivorship research, tumor registries in, 1305
Candidiasis, chronic disseminated, in acute leukemia, 1349
Capecitabine, for taxane-refractory/failing breast cancer, 1759
Capsase(s)
in apoptosis priming, for prostate cancer, 2297
2-methoxyestradiol–induced activation of, in gastric cancer, 500
Carbon dye mapping, of sentinel nodes, in melanoma, 535
Carboplatin
vs. cyclophosphamide plus vincristine, for small cell lung cancer, 601
with liposomal doxorubicin, for cervical cancer, 2327
for nonsmall cell lung cancer, with/without radiotherapy, 2142

with paclitaxel
for head and neck cancer, 2334
for nonsmall cell lung cancer, performance status and, 2639
with paclitaxel and long-term continuous-infusion 5-fluorouracil, for advanced squamous cell carcinoma, 642
with radiotherapy, for nonsmall cell lung cancer, 1213
in sequential combination, for nonsmall cell lung cancer, 146
twice-daily amifostine with, for refractory pediatric cancers, 914, 3170 (erratum)
Carcinoembryonic antigen, in portal and peripheral blood, in colorectal cancer, prognosis and, 1251
Carcinoid tumors
appendiceal, incidence trends and risk factors for, 2204
foregut/midgut, cisplatin and etoposide for, 1101
incidence trends and risk factors for, 2204
Carcinomatosis, peritoneal, from colorectal cancer, resection and intraperitoneal chemotherapy for, 71
Cardiac arrest, survival after, predictors of, 1905
Cardiopulmonary resuscitation, survival after, predictors of, 1905
Carmustine, with/without interferon-α, plus radiotherapy, for glioma, 420
Carotenoids, antioxidant, ovarian cancer risk and, 2318
Carotid stenosis, after radiotherapy for nasopharyngeal cancer, 2357
Castleman disease, treatment of, 670
β-Catenin
in hepatocellular carcinoma, 136
in tumor budding, in colorectal cancer tumor budding, 2539
Catenin/E-cadherin complex, in prostate cancer, prognosis and, 2786
Cathepsin D, in breast cancer, prognosis and, 2957
Catheters, standard open-ended vs. Groshong, for central venous ports, 1204
CD44
in preneoplastic pulmonary lesions, 1231
soluble serum, in B-cell chronic lymphocytic leukemia, prognosis and, 713
CD44 variant 6, in tumor budding, in colorectal cancer, 2539
CD95, in peripheral blood vs. cytotoxic lymphocytes, in hepatocellular carcinoma, 2136
Cell lines, prostate cancer, apoptosis priming for, capsases in, 2297
Central lymphatic irradiation, for follicular lymphoma, hematologic recovery after, 1074
Central nervous system tumors. *See also specific types and sites*
pediatric, medical and neurocognitive late effects in, 2709
rehabilitation for, 1029
Central venous ports, standard open-ended vs. Groshong catheter for, 1204
c-*erb* B-2, in nephroblastoma, prognosis and, 3120
c-*erb* B-2 DNA amplification, in breast cancer, 2965
Cerebral metastasis
in lung cancer, after high-dose preoperative chemoradiotherapy, 160
in neonatal alveolar rhabdomyosarcoma, 1613
rehabilitation for, 1029
in rhabdomyosarcoma, routine brain scans for at diagnosis, 121
Cerebrospinal fluid, lipid-associated sialoprotein in, brain tumors and, 856
Cervical cancer
FIGO staging system for, 797
hemoglobin levels in, response to chemoradiotherapy and, 903
histologic subtype of, prognosis and, 2471
$p27^{Kip1}$ in, 3005
recurrent, carboplatin and liposomal doxorubicin for, 2327
urethra-sparing cystectomy for, 1864
Chemiluminescence assay
for GD2 synthase, in neuroblastoma, 924
for periostin, in nonsmall cell lung cancer, 843
Chemoradiotherapy
vs. accelerated radiotherapy, for head and neck cancer, 2856
for cervical cancer, treatment response in, hemoglobin levels and, 903
for nonsmall cell lung cancer, 1213
increased cerebral metastasis after, 160
for rectal cancer, fatigue and, 1725
Chemotherapy. *See also specific agents and cancers*
for acute lymphoblastic leukemia, proline-directed protein kinase F_A and, 1753
for acute myelogenous leukemia, 7, 1059
for advanced solid tumors, 1567
alkylating agents in, gemcitabine as modulating agent for, 194
azoospermia after, testicular sperm extraction with intracytoplasmic sperm injection in, 1632
for bladder cancer, 2993
bone marrow toxicity of, 2419
for breast cancer, 2247, 2508, 2517
in early-stage disease, 1354
in older women, 730
salvage, 2267
^{99m}-Tc-MIBI scintigraphy in prediction of, 232
in younger women, quality of life and, 1288
for Castleman disease, disease, 670
central venous ports for, standard open-ended vs. Groshong catheter for, 1204
for cervical cancer, 2327
for colorectal cancer, patient selection for, 1435
combination
for nonsmall cell lung cancer, 146
performance status and, 2639
topotecan and gemcitabine for, 414
dose-escalated CHOP, for diffuse lymphoma, 207

for esophageal cancer, in trimodality therapy, 1273
for esophageal/gastroesophageal junction cancer, followed by chemoradiation and surgery, 279
for fibromatosis, 1259
for glioma, 1936
for head and neck cancer, 326, 814, 2334, 2364
hepatic artery–infusion, for colorectal liver metastases, 2746
for hepatic lymphoma, 2023
for hepatic metastases, from germ cell tumors, 578
hepatitis B virus reactivation and, 2927
for Hodgkin's disease, with large mediastinal involvement, 453
hyperthermic pleural perfusion with, 2197
for inflammatory breast cancer, 1775
infusional, for HIV-related non-Hodgkin's lymphoma, 200
intraperitoneal, for peritoneal carcinomatosis, from colorectal cancer, 71
for large cell lung cancer, 1108
for lung cancer, 2158
for maxillary sinus cancer, 1495
for metastatic melanoma, 609
for müllerian tumors, 1156
for myelodysplastic syndrome, 1999
myelotoxicity of, pathogenesis of, 2419
for neuroendocrine tumors, 1101
for nonsmall cell lung cancer, 146, 595, 814, 2391
  performance status and, 2639
  in second-line therapy, 2902
for ovarian cancer, 1856
  with tumor debulking, 3585
for pancreatic cancer, 569
for pediatric CNS tumors, medical and neurocognitive late effects of, 2709
for pharyngolaryngeal cancer, 1504
for pleural mesothelioma, 650
prophylactic, for hereditary breast/ovarian cancer, attitudes toward in English, French and Canadian women, 959
for prostate cancer, 2435
with radiotherapy. *See* Chemoradiotherapy
for renal cell carcinoma, 519
resistance to, PSC 833 for, 1577
for retinoblastoma, resistance to, 2933
for rhabdomyosarcoma of parotid region, 3135
for small cell lung cancer, 601
somatostatin receptor–targeted, for ovarian cancer, 1168
stomatitis in, homeopathic medication (TRAUMEEL S) for, in children undergoing stem cell transplant, 684
for testicular germ cell tumors, in HIV infection, antiretroviral therapy and, 1460
twice-daily amifostine with, for refractory pediatric cancers, 914, 3170 (erratum)
vasoactive intestinal peptide analog in, for enhanced chemosensitivity and reduced toxicity, 2172
Chest computed tomography, in staging of T1 extremity soft tissue sarcomas, 863
Children. *See also specific cancers of childhood, e.g.,* Leukemia
  CNS tumors in, medical and neurocognitive late effects in, 2709
  febrile neutropenia in, risk factors for bacteremia in, 909
  hemangiopericytoma in, 2692
  Hodgkin's disease in, Epstein-Barr virus and, in China, 1621
  non-Hodgkin's lymphoma in, second malignancy after, 1959
  osteosarcoma in, HER-2/*neu* oncogene amplification in, 677
  refractory cancer in, twice-daily amifostine for, 914, 3170 (erratum)
  solid tumors in, increasing incidence of, in England, 1967
  stem cell transplant in, chemotherapy-induced stomatitis in, TRAUMEEL S for, 684
  upper respiratory tract cancer in, chromosomal translocation 15;19 and, 1195
China
  nasopharyngeal cancer in, radiotherapy for, 2126
  pediatric Hodgkin's disease in, Epstein-Barr virus and, 1621
Chinese-Americans, breast cancer hormone receptor status in, tumor characteristics and, 37
Cholangiocarcinoma, intrahepatic mass-forming, staging of, 2374
Cholecystokinin 8, in cancer-associated anorexia, 629
CHOP regimen
  dose-escalated, for diffuse lymphoma, 207
  for primary hepatic lymphoma, 2023
Chromosomal abnormalities, in papillary thyroid cancer, 2529
Chromosomal translocation 15;19, pediatric upper respiratory tract cancer and, 1195
Chromosome 22 loss/gains, in meningioma, tumor aggressiveness and, 377
Chronic leukemia. *See* Leukemia
Cigarette smoking
  K-*ras* mutation and, in lung cancer, 1525
  in unresectable lung cancer, 2609
Cisplatin
  with amifostine, for breast cancer, 2517
  with doxorubicin and interferon -2b, for pleural mesothelioma, 650
  for head and neck cancer, 814
  hyperthermic pleural perfusion with, 2197
  for neuroendocrine tumors, 1101
  for nonsmall cell lung cancer
    with pemetrexed disodium, 595
    performance status and, 2639
  for ovarian cancer, 1856
  for pancreatic cancer, 569
  for pharyngolaryngeal cancer, 1504

vasoactive intestinal peptide analog with, for enhanced chemosensitivity and reduced toxicity, 2172
c-kit mutation, in family with gastrointestinal stromal tumors and urticaria pigmentosa, 657
Clonality, in intraductal papillary-mucinous pancreatic tumor, 1807
C-methionine positron emission tomography, for low-grade glioma, prognosis and, 1541
Cognitive function
in childhood CNS tumor survivors, 2709
fatigue and, 988, 1694
rehabilitation for. *See* Cancer rehabilitation
Colon cancer. *See also* Colorectal cancer
matrix metalloproteinase-9 in, vs. in rectal cancer, 2680
Colon carcinoids, incidence trends and risk factors for, 2204
Colony-stimulating factors, for acute myelogenous leukemia, 1059
Colony stimulating factors, in ovarian cancer, 2837
Colorectal cancer
advanced, conditional median survival in, 2211
angiopoietin-1/2 and, 1138
annexin II overexpression in, stromal tenascin-C overexpression and, 1419
circulating tumor cells in, prognosis and, 1251
epidermal growth factor receptor reactivity in, staging and, 1331
gelatinases in, 2680
matrix metalloproteinase-9 in, 2680
peritoneal carcinomatosis in, resection and intraperitoneal chemotherapy for, 71
$pp60^{c\text{-}src}$ in, C-terminal Src kinase activity and, 61
preoperative chemoradiation for, fatigue and, 1725
preoperative radiotherapy for, Stockholm II trial of, 896
radiotherapy for, neutrophilic granulocyte function and, 2444
stage II, chemotherapy for, patient selection for, 1435
stage III, subdivision of, 2754
subsite-specific incidence rate and disease stage in, 2547
tumor budding in, CD44 variant 6 and nuclear β-catenin in, 2539
urethra-sparing cystectomy for, in women, 1864
Comparative genomic hybridization
of esophageal cancer, 2769
of postirradiation sarcoma, 1993
Complementary medicine, for fatigue, 1714
Compression garments, for lymphedema, 980
Computed tomography
for brain metastasis, in rhabdomyosarcoma, 121
chest, in staging of T1 extremity soft tissue sarcomas, 863
vs. 18-fluoro-2-deoxyglucose PET, in nasopharyngeal cancer, 434
in lung cancer screening, 153, 3051
Conditional survival, in advanced cancers, 2211
Consanguinity, leukemia and lymphoma and, 1
Consent, for pediatric research for leukemia, 691
Corticosteroids, for fatigue, 1714
Coumarin, for lymphedema, 980
COX-2
eIF4E and, in head and neck dysplasia, 1888
in transitional cell carcinoma of bladder, tumor invasiveness and survival and, 188
COX-2 inhibitors, for fatigue, 1714
CpG hypermethylation of promoter region, estrogen receptor-β inactivation by, in prostate cancer, 2076
Cranial irradiation
in children, late neurocognitive effects of, 2709
for high-risk acute lymphoblastic leukemia, 15
Craniofacial prostheses, bone-anchored, patient satisfaction with, 3045
C-terminal Src kinase activity, $pp60^{c\text{-}src}$ and, in colorectal cancer, 61
Cutaneous metastasis, in neonatal alveolar rhabdomyosarcoma, 1613
Cutaneous tumors. *See* Skin cancer
Cyclin-dependent kinase inhibitors, in ovarian cancer, cell proliferation and apoptosis and, 1177
Cyclooxygenase-2
eIF4E and, in head and neck dysplasia, 1888
in transitional cell carcinoma of bladder, tumor invasiveness and survival and, 188
Cyclooxygenase-2 inhibitors, for fatigue, 1714
Cyclophosphamide
dose-escalated, for diffuse lymphoma, 207
infusional, for HIV-related non-Hodgkin's lymphoma, 200
with mitoxantrone, for breast cancer, 2508
for myelodysplastic syndrome, 1999
for primary hepatic lymphoma, 2023
with vincristine, vs. carboplatin, for small cell lung cancer, 601
Cyclosporin A
for acute myelogenous leukemia, 1059
for cytopenia, in chronic lymphocytic leukemia, 2016
CYFRA 21-1, in bladder cancer monitoring, 2820
Cystectomy, urethra-sparing, in women, 1864
Cytarabine, with liposomal daunorubicin, for acute myelogenous leukemia, 7
Cytokeratin fragments 21-1, in bladder cancer monitoring, 2820
Cytokeratins 20 and 7, in pleural mesothelioma, vs. in metastatic adenocarcinoma, 2727
Cytokines
fatigue and, 1684, 1714
in nonsmall cell lung cancer, prognosis and, 2399
Cytopenia, in chronic lymphocytic leukemia, cyclosporin A for, 2016
Cytosine arabinoside
for acute myelogenous leukemia, 1059
for myelodysplastic syndrome, 1999
for primary hepatic lymphoma, 2023
Cytotoxic lymphocytes, Fas antigen in, in hepatocellular carcinoma, 2136

D

Dacarbazine, for melanoma, 2190
Daunorubicin
for acute myelogenous leukemia, 1059
liposomal, with cytarabine, for acute myelogenous leukemia, 7
Decitabine, for acute myelogenous leukemia, 1059
Deconditioning, rehabilitation for. *See* Cancer rehabilitation
Depression
fatigue and, 1684, 1694
after lung cancer surgery, physician support and, 1926
in unresectable lung cancer, 2609
Desferrioxamine, for hepatocellular carcinoma, 3093
Dexamethasone, for fatigue, 1714
Dextroamphetamine, for fatigue, 1714
1-1,Dichlorodiphenildichloroethane, in adrenocortical cancer, prognosis and, 1385
Diet
cancer-related fatigue and, 988
ovarian cancer and, 2318
Diethyl-maleate, in apoptosis priming, for prostate cancer, 2297
Disability. *See* Cancer rehabilitation
Disseminated peritoneal adenomucinosis, pseudomyxoma peritonei in, vs. in peritoneal mucinous carcinomatosis, 85
Diuretics, for lymphedema, 980
DNA/cytokeratin flow cytometry, in bladder cancer, for recurrence detection, 2811, 2820
DNA fragmentation, in pulmonary artery sarcoma, 1237
DNA methylation, in prostate cancer, prognosis and, 2786
DNA mismatch repair genes, in bronchioloalveolar cancer, 2898
DNA ploidy
in gastric cancer, prognosis and, 294
in renal cell carcinoma, prognosis and, 2280
Docetaxel
with cisplatin, for nonsmall cell lung cancer, performance status and, 2639
with gemcitabine, for nonsmall cell lung cancer, 2391, 2902
for lung cancer, 2158
with vinorelbine, for nonsmall cell lung cancer, 2391
Do not resuscitate orders, predictors of survival after CPR and, 1905
Doxorubicin
with cisplatin and interferon -2b, for pleural mesothelioma, 650
dose-escalated, for diffuse lymphoma, 207
gemcitabine as modulating agent for, 194
infusional, for HIV-related non-Hodgkin's lymphoma, 200
liposomal
with carboplatin, for cervical cancer, 2327
for glioma, 1936
for primary hepatic lymphoma, 2023
for soft tissue sarcoma, wild type *p53* and, 1556
vasoactive intestinal peptide analog with, for enhanced chemosensitivity and reduced toxicity, 2172
Drug abuse, in unresectable lung cancer, 2609
Ductal carcinoma in situ of breast, mastectomy for, vs. breast-conserving therapy, 23
Dysplastic nodules, as preneoplastic lesions in, in hepatocellular carcinoma, 2733

E

Early Lung Cancer Action Project, 153
E-cadherin
in lobular carcinoma in situ of breast, risk of subsequent cancer and, 738
in prostate cancer, prognosis and, 2786
E-cadherin gene mutations, as indication for prophylactic total gastrectomy, 181
Economic factors, in prostate cancer, 2796
Editor-in-chief's report, 2235
Educational materials, on genetic testing, for *BRCA1/2* founder mutations, in Ashkenazi Jews, 932
eIF-4E, COX-2 and, in head and neck dysplasia, 1888
eIF-4E/2α, in bronchioloalveolar vs. squamous cell lung cancer, 2158
eIF-4G, in squamous cell lung cancer, 822
Elastic compression garments, for lymphedema, 980
Elderly
breast conservation therapy for, 1092
head and neck cancer in, comorbidity and survival in, 2109
mammography in, recommendations for, 1299
pelvic and aortic lymphadenectomy for, 2562
ELISA test, urinary bladder carcinoma antigen, for recurrence detection, 2811, 2820
Embolization
of meningiomas, clinicopathologic assessment and grading after, 701
portal vein, preoperative, in hepatocellular carcinoma, 2384
Embryonal rhabdomyosarcoma, with skin and brain metastases, 1613
Endobronchial brachytherapy, for tracheobronchial tumors, massive hemoptysis after, 2623
Endocrine pancreatic tumors, cisplatin and etoposide for, 1101
Endocrine therapy, for prostate cancer, mortality trends and, 2309
Endometrial cancer
androgen receptor CAG repeat in, in Israeli Jews, 1190
hysterectomy for, comorbid illness and complications of, racial factors in, 950
loss of motility-related protein 1 and integrin α3 expression in, prognosis and, 542
urethra-sparing cystectomy for, 1864
Endometrial polyps, risk factors for, in tamoxifen-treated breast cancer, 1151
Endometrioid adenocarcinoma of uterine corpus, in

women <50, clinicopathologic correlates of anatomic location in, 2578
Endothelial cancer, vascular endothelial growth factor/flk-1(KDR) receptor pathway in, 2569
End-stage care, predictors of survival after CPR in, 1905
England
attitudes toward preventive strategies for hereditary breast/ovarian cancer in, 959
increasing incidence of pediatric solid tumors in, 1967
Ependymoma, ovarian, tumor imprint cytology of, 3165
Epidermal growth factor, in ovarian cancer, ezrin and, 3068
Epidermal growth factor receptor
in colon adenocarcinoma, staging and, 1331
in nephroblastoma, prognosis and, 3120
Epithelial cell adhesion molecule, regulation of by tumor necrosis factor á, 620
Epstein-Barr virus, in pediatric Hodgkin's disease, in China, 1621
Epstein-Barr virus Rta protein, in nasopharyngeal cancer, diagnostic utility of, 1872
Erratum, 3170
Esophageal cancer
allogeneic blood transfusion in, prognosis and, 1913
chemotherapy for, followed by chemoradiation and surgery, 279
comparative genomic hybridization of, 2769
lymphatic vessel invasion in, prognosis and, 2228
rising incidence of in white males, demographic variations in, 549
trimodality therapy for, 1273
vascular endothelial growth factor in, 663
Estrogen receptor-ß inactivation, in prostate cancer, 2076
Estrogen receptor status, in breast cancer, race/ethnicity and, 37
Estrogen replacement therapy, in sexuality rehabilitation, 1008
Ethanol injection, for hepatocellular carcinoma
prognostic factors for, 126
with/without transcatheter arterial chemoembolization, 1516
Ethnicity. *See* Race/ethnicity
Etoposide
dose-escalated, for diffuse lymphoma, 207
infusional, for HIV-related non-Hodgkin's lymphoma, 200
for neuroendocrine tumors, 1101
for primary hepatic lymphoma, 2023
twice-daily amifostine with, for refractory pediatric cancers, 914, 3170 (erratum)
Eukaryotic translation initiation factors 4E and 2α, in bronchioloalveolar vs. squamous cell lung cancer, 2158
Ewing sarcoma
ifosfamide with radiotherapy for, toxicity of, 1550
insulin-like growth factor type 1 and IGF binding protein-3 in, prognosis and, 2941
Exercise
breast cancer risk and, 1638
in fatigue management, 988, 1689, 1699
for lymphedema, 980
Ezrin, in ovarian cancer, 3068

F

Facial prostheses, bone-anchored, patient satisfaction with, 3045
Fallopian tube cancer, urethra-sparing cystectomy for, 1864
Familial adenomatous polyposis coli, hepatocellular carcinoma in, *APC* inactivation and, 332
Farnesyl transferase inhibitors, for acute myelogenous leukemia, 1059
Fas antigen, in peripheral blood vs. cytotoxic lymphocytes, in hepatocellular carcinoma, 2136
Fas ligand, serum soluble, in bladder cancer, 287
Fatigue
anemia and, 1678, 1684, 1719
assessment of, 1733
biologic basis of, 1678
cognitive function and, 988, 1694
cytokines in, 1684
depression and, 1684, 1694
drug therapy for, 988, 1714
epidemiology of, 1733
exercise for, 988, 1689, 1699
infection and, 1678, 1684
interferon-related, 1664
management of, 988, 1689, 1699
muscle wasting and, 1669
overview of, 1657
patient's perspective on, 1662
research funding for, 1737
specialty clinic for, 1708
wasting and, 1669, 1684
Febrile neutropenia, in children, risk factors for bacteremia in, 909
Fentanyl
conversion from IV to transdermal for, 3056
intravenous methadone substitution for, 1919
Fertility
maintenance of, in epithelial ovarian cancer, 2412
ovulation induction for, after conservative management of borderline ovarian tumors, 320
α-Fetoprotein, as prognostic factor, for hepatocellular carcinoma treated with percutaneous ethanol injection, 126
224-Fetoprotein, as prognostic factor, for hepatocellular carcinoma treated with percutaneous ethanol injection, 126
Fever, fatigue and, 1684
FGFR3, thanatophoric dysplasia mutations in, in bladder cancer, 2555
Fibroadenoma with atypia, breast cancer risk and, 30
Fibroblast growth factor receptor 3, thanatophoric dysplasia mutations in, in bladder cancer, 2555

Fibromatosis, advanced aggressive, methotrexate and vinblastine for, 1259
15;19 translocation, pediatric upper respiratory tract cancer and, 1195
FIGO staging system, for cervical cancer, 797
Filipino-Americans, breast cancer hormone receptor status in, tumor characteristics and, 37
flk-1(KDR) receptor, vascular endothelial growth factor and, in endometrial cancer, 2569
Flow cytometry
  DNA/cytokeratin, in bladder cancer, for recurrence detection, 2811, 2820
  in gastric cancer, prognosis and, 294
  in renal cell carcinoma, prognosis and, 2280
Fludarabine
  for acute myelogenous leukemia, 1059
  for myelodysplastic syndrome, 1999
18-Fluoro-2-deoxyglucose positron emission tomography
  vs. ^{99m}Tc tetrofosmin SPECT and CT, in nasopharyngeal cancer, 434
  for head and neck cancer, cost effectiveness of, 2341
  for staging in radical radiotherapy candidates in nonsmall cell lung cancer, 886
5-Fluorouracil
  for colorectal liver metastases, 2746
  with gemcitabine, for advanced solid tumors, 1567
  intraperitoneal, for peritoneal carcinomatosis, from colorectal cancer, 71
  long-term continuous-infusion, with paclitaxel and carboplatin, for advanced squamous cell carcinoma, 642
  for maxillary sinus cancer, 1495
  for pharyngolaryngeal cancer, 1504
  with radiotherapy, for rectal cancer, fatigue and, 1725
Folinic acid, for colorectal liver metastases, 2746
Follicular lymphoma, central lymphatic irradiation for, hematologic recovery after, 1074
Foregut carcinoids, cisplatin and etoposide for, 1101
Fractures, pathologic, rehabilitation and, 1020
Frameshift mutations, in ovarian cancer, 2829
France, attitudes toward preventive strategies for hereditary breast/ovarian cancer in, 959
Ftorafur, with uracil and leucovorin, for head and neck cancer, 326

G

Gallbladder cancer, hepatic metastasis in, 340
Ganglioneuroblastoma, histopathology and MYCN status of, 2699
Ganglioneuroma, histopathology and MYCN status of, 2699
Gardner syndrome, hepatocellular carcinoma in, *APC* inactivation and, 332
Gastrectomy, prophylactic total, germline E-cadherin gene mutations as indication for, 181
Gastric cancer
  DNA aneuploidy in, prognosis and, 294
  glucose transporter-1 in, prognosis and, 634
  immunohistochemically detected nodal micrometastases in, prognosis and, 753
  interleukin-18 in, prognosis and, 2050
  K-*ras*-2 in, prognosis and, 294
  lymph node micrometastases in, genetic detection of, 2056
  2-methoxyestradiol-induced caspase-3 activation in, apoptosis and, 500
  MGMT-methylation in, *K-ras* and, 2760
  microsatellite instability in, 92
  mucin in, prognosis and, 1427
  p53 and $p21^{WAF1/CIP1}$ in, 1828
  prophylactic total gastrectomy for, germline E-cadherin gene mutations as indication for, 181
  S-phase fraction n, prognosis and, 294
Gastroesophageal junction cancer, chemotherapy for, followed by chemoradiation and surgery, 279
Gastrointestinal stromal tumors, with urticaria pigmentosa, kit mutation and, 657
GD2 synthase, in neuroblastoma, 924
Gelatinases, in colon vs. rectal cancer, 2680
Gemcitabine
  with 5-fluorouracil, for advanced solid tumors, 1567
  with ifosfamide and doxorubicin, as modulating agent, 194
  for nonsmall cell lung cancer, 830
    with docetaxel, 2391, 2902
    with gemcitabine, 2639
    performance status and, 2639
    in sequential combination, 146
  with paclitaxel, for bladder cancer, 2993
  for pancreatic cancer, 569
  with topotecan, for advanced tumors, 414
  vasoactive intestinal peptide analog with, for enhanced chemosensitivity and reduced toxicity, 2172
Gemtuzumab ozogamicin
  for acute myelogenous leukemia, 1059
  venoocclusive disease and, 406
Gene expression profiling, for hepatocellular carcinoma, 395
Genes. *See specific genes and gene families*
Genetic polymorphisms, affecting androgen biosynthesis, prostate cancer and, 1130
Genetic testing, *BRCA1/2* founder mutations in Ashkenazi Jews, educational materials on, 932
Germany, brain tumors epidemiology in, 3155
Germ cell tumors
  hepatic metastasis in, multimodality treatment of, 578
  in HIV infection, 1460
  mediastinal teratoma, mature vs. immature, apoptosis and proliferative activity in, 1798
  testicular, MAGE-A4 in, 2778
Germline E-cadherin gene mutations, as indication for prophylactic total gastrectomy, 181
Giant cell tumor of bone
  osteoprotegerin for, 460
  receptor activator of nuclear factor-*K*B ligand in, 460

Gleason grading system, vs. WHO system, for prostate cancer, 311
Glioma
liposomal doxorubicin for, 1936
low-grade, C-methionine PET in, prognosis and, 1541
radiotherapy for, with carmustine with/without interferon-α, 420
rehabilitation for, 1029
taxane analog BAY 59-8862 for, 3085
Gliomas, rare *HRAS1* alleles and, 2920
Glucocorticoids, for fatigue, 1714
Glucose transporter-1, in gastric cancer, prognosis and, 634
Glut1
in gastric cancer, prognosis and, 634
in ovarian cancer, prognosis and, 1144
γ-Glutamyl cysteine synthetase, in nonsmall cell lung cancer, 2911
Glutathione, in apoptosis, in prostate cancer, 2297
P-Glycoprotein antagonist PSC 833, with vinblastine, for advanced solid tumors, 1577
Granulocyte colony-stimulating factors, for acute myelogenous leukemia, 1059
Granulocyte-macrophage colony-stimulating factors, for acute myelogenous leukemia, 1059
Granulocytes, neutrophilic, irradiation effects on, 2444
Groshong catheter, vs. standard open-ended catheter, for central venous ports, 1204
Gynecologic cancers. *See also specific types*
ACE inhibitor protective effect for, 2462
urethra-sparing cystectomy for, 1864

H

Head and neck cancer
ACE inhibitors prophylaxis for, 2462
advanced/recurrent, ifosfamide, cisplatin and cis-retinoic acid for, 814
carboplatin and paclitaxel for, 2334
chemoradiotherapy vs. accelerated radiotherapy for, 2856
in elderly, comorbidity and survival in, 2109
fluorodeoxyglucose 18-F PET for, cost effectiveness of, 2341
intraarterial polyoxyethylated castor oil–free paclitaxel for, 2592
oral, pRb2/p130 in, clinicopathologic correlates of, 2117
oral uracil-ftorafur with leucovorin for, 326
pharyngolaryngeal, chemotherapy for, 1504
postirradiation hypothyroidism in, 2892
pretreatment hypothyroidism in, 1512
thalidomide for, 2364
tongue, metastasis in, predictors of, 1881
tonsillar, staging of, 1484
vascular endothelial growth factor in, nodal metastasis and, 556
verrucous, National Cancer Data Base survey of, 110
Head and neck dysplasia, COX-2 and *eIF4E* in, 1888
Health Care Cost and Utilization Project analysis, of racial factors in comorbid illness and complications in hysterectomy for endometrial carcinoma, 950
Hemangiopericytoma, pediatric, 2692
Hematologic cancers
homoharringtonine for, 1591
lactic acidosis in, 2237
Hematopoietic stem cell transplantation
for acute myelogenous leukemia, 1059
illness intrusiveness after, 3147
osteoporosis after, pathogenesis of, 2419
pediatric, chemotherapy-induced stomatitis in, TRAUMEEL S for, 684
rehabilitation after, 998
Hemoglobin levels, in cervical cancer, response to chemoradiation and, 903
Hemoptysis, massive, after endobronchial brachytherapy, 2623
Hepatic artery infusion, for colorectal liver metastases, 2746
Hepatic cholangiocarcinoma, mass-forming, staging of, 2374
Hepatic lymphoma, combination chemotherapy for, 2023
Hepatic metastasis
from gallbladder carcinoma, 340
from germ cell tumors, multimodality treatment of, 578
Hepatic veins, renal cell carcinoma invasion of, 1836
Hepatic venoocclusive disease, Mylortag (gemtuzumab ozogamicin) and, 406
Hepatitis B virus, reactivation of in chemotherapy, 2927
Hepatoblastoma, small cell undifferentiated histology in, prognosis and, 3130
Hepatocellular carcinoma
apoptosis in, 2733
candidate marker genes for, 395
β-catenin in, 136
dysplastic nodules as preneoplastic lesions in, 2733
in familial adenomatous polyposis coli, *APC* inactivation and, 332
iron chelators for, 3093
percutaneous ethanol injection for
prognostic factors for, 126
with/without transcatheter arterial chemoembolization, 1516
preoperative portal vein embolization in, 2384
Hepatosplenic candidiasis, in acute leukemia, 1349
Her-2/*neu*, in lung cancer, prognosis and, 1898
HER-2/*neu* DNA amplification, in breast cancer, 2965
HER-2/*neu* oncogene amplification, in pediatric osteosarcoma, 677
Hereditary cancer, breast/ovarian, preventive strategies for, attitudes toward in English, French and Canadian women, 959
High-grade prostatic intraepithelial neoplasia, prostate cancer risk and, 524

Hispanics. *See also* Race/ethnicity
breast cancer hormone receptor status in, tumor characteristics and, 37
mammography in, recommendations for, 1299
HIV infection. *See* Human immunodeficiency virus infection
hMLH1, in bronchioloalveolar cancer, 2898
hMSH2/6, in bronchioloalveolar cancer, 2898
Hodgkin's disease. *See also* Lymphoma
acute lymphocytic, consanguinity and, 1
advanced, with large mediastinal involvement, treatment of, 453
diagnosis and histologic classification of, expert review of, 218
HIV-related, vs. HIV-related non-Hodgkin's lymphoma, 2738
lactic acidosis in, 2237
pediatric, Epstein-Barr virus and, in China, 1621
Homeopathic medication (TRAUMEEL S), for chemotherapy-induced stomatitis, in children undergoing stem cell transplant, 684
Homoharringtonine, for leukemia, 1591
Hormonal therapy, for prostate cancer, mortality trends and, 2309
Hormone receptor status, in breast cancer, race/ethnicity and, 37
Hormone replacement therapy, in sexuality rehabilitation, 1008
HRAS1 alleles, brain tumors and, 2920
H-*ras* antisense oligonucleotide ISIS 2503, continuous fusion of, for advanced cancer, 1265
HT-29, for enhanced chemosensitivity and reduced toxicity, 2172
hTERT mRNA, in squamous cell lung cancer, during multistage carcinogenesis, 849
HuM195, for acute myelogenous leukemia, 1059
Human herpesvirus-8–associated malignancies, p53 and LANA in, 3076
Human immunodeficiency virus infection
germ cell tumors in, 1460
non-Hodgkin's lymphoma in
vs. Hodgkin's disease, 2738
incidence trends and, 2948
infusional cyclophosphamide, doxorubicin and etoposide for, 200
Human leukocyte antigen–G, soluble serum, in melanoma, 369
Human papillomavirus 16 DNA, in tonsillar cancer, 2875
Human papillomavirus–positive oropharyngeal squamous cell carcinoma, radiosensitivity of, 805
Human prostate specific glandular kallikrein 2, diagnostic utility of, 2975
Hyaluronan, in pleural fluid, in malignant pleural mesothelioma, prognosis and, 1224
Hyperthermic pleural perfusion, chemotherapy with, 2197
Hypomethylating agents, for acute myelogenous leukemia, 1059
Hypothyroidism
postirradiation, in head and neck cancer, 2892
pretreatment, in head and neck cancer, 1512
Hypoxia-inducible factor-1α, in oligodendrogliomas, prognosis and, 165
Hysterectomy
for endometrial cancer, comorbid illness and complications of, racial factors in, 950
prophylactic, attitudes toward in English, French and Canadian women, 959

I

Idarubicin
for acute myelogenous leukemia, 1059
for myelodysplastic syndrome, 1999
Ifosfamide
gemcitabine as modulating agent for, 194
for head and neck cancer, 814
for ovarian cancer, 1856
for primary hepatic lymphoma, 2023
with radiotherapy, for sarcoma, toxicity of, 1550
twice-daily amifostine with, for refractory pediatric cancers, 914, 3170 (erratum)
IKKα, in oral squamous cell carcinoma, 3037
Immunofluorescence assay, for GD2 synthase, in neuroblastoma, 924
Immunotherapy
long-term, for renal cell carcinoma, 2286
for metastatic melanoma, 609
Imprint cytology, in ovarian ependymoma, 3165
Indium 111–pentetreotide–guided surgery, for pheochromocytoma and medullary thyroid cancer, 263
Infantile hemangiopericytoma, 2692
Infections
after bone marrow transplant, quality of life and, 3147
fatigue and, 1678, 1684
Inferior vena cava, renal cell carcinoma invasion of, 1836
Infertility
ovulation induction for, after conservative management of borderline ovarian tumors, 320
postchemotherapy, testicular sperm extraction with intracytoplasmic sperm injection in, 1632
Inflammatory breast cancer, paclitaxel for, 1775
Infliximab, for fatigue, 1714
Informed consent, for pediatric research for leukemia, 691
Inguinal node metastases, in anal carcinoma, management of, 77
INK4A gene products, in osteosarcoma, 3062
Insulin-like growth factor
and IGF binding protein-3 in, in Ewing sarcoma, prognosis and, 2941
lactic acidosis and, 2237
Integrin α3, in endometrial cancer, prognosis and, 542
Interferon-α
with carmustine plus radiotherapy, for glioma, 420
long-term, for renal cell carcinoma, 2286

for melanoma, soluble human leukocyte antigen–G serum level in, 369
for metastatic renal cancer, 761
for renal cell carcinoma, 519
Interferon, fatigue and, 1664
Interferon-α-2b, with doxorubicin and cisplatin, for pleura mesothelioma, 650
Interleukin-1α, in ovarian cancer, ezrin and, 3068
Interleukin-2
long-term, for renal cell carcinoma, 2286
with tamoxifen, for metastatic melanoma, 609
Interleukin-8, vascular endothelial growth factor and, in nonsmall cell lung cancer, 2628
Interleukin-18, in gastric cancer, prognosis and, 2050
International Neuroblastoma Pathology Classification, in prognostic evaluation, 2451
Intraductal papillary-mucinous pancreatic tumor, clonality and field cancerization in, 1807
Intrahepatic cholangiocarcinoma, mass-forming, staging of, 2374
Intratumoral microvessel density, in pancreatic cancer, prognosis and, 1788
Iridium-192 interstitial implant, for prostate cancer, long-term results of, 2084
Irinotecan, vasoactive intestinal peptide analog with, for enhanced chemosensitivity and reduced toxicity, 2172
Iron chelators, for hepatocellular carcinoma, 3093
ISIS 2503, continuous fusion of, for advanced cancer, 1265

J

Japan
breast cancer in, BRCA1 in, prognosis and, 54
lung cancer screening in, 588
screening-detected recurring neuroblastoma in, 349
Japanese-Americans, breast cancer hormone receptor status in, tumor characteristics and, 37
Jews
Ashkenazi
BRCA1/2 and *APC* founder mutations in, frequency of, in Australia, 440
BRCA1/2 founder mutations in, genetic testing for, educational materials on, 932
endometrial cancer in, androgen receptor CAG repeat in, 1190

K

Kaposi sarcoma, apoptosis in, p53 and LANA in, 3076
Karyometry, in thyroid cancer diagnosis, 1818
Ki-67, in pancreatic cancer, prognosis and, 1788
Ki-67 proliferative index, for soft tissue sarcoma, prognosis and, 869
Kidney. *See under* Renal
kit mutation, in family with gastrointestinal stromal tumors and urticaria pigmentosa, 657
K-*ras* mutation(s)
in intraductal papillary-mucinous pancreatic tumors, 1807
in lung cancer, smoking and, 1525
MGMT-methylation and, in gastric cancer, 2760
in pancreatic cancer, 488
K-*ras* mutations, in gastric cancer, prognosis and, 294
Ku heterodimer, in bladder cancer, 2484

L

Lactic acidosis, in hematologic cancers, 2237
Lamivudine, for prevention of chemotherapy-related hepatitis B virus reactivation, 2927
LANA, apoptosis in HHV-8–associated malignancies and, 3076
Laparoscopic radical nephrectomy, 1843
Large cell lung cancer. *See also* Lung cancer
adjuvant chemotherapy for, 1108
Laryngeal cancer
15;19 translocation and, in children, 1195
chemotherapy for, 1504
verrucous, National Cancer Data Base survey of, 110
Latency-associated nuclear antigen, apoptosis in HHV-8–associated malignancies and, 3076
Latinas. *See also* Race/ethnicity
breast cancer hormone receptor status in, tumor characteristics and, 37
mammography in, recommendations for, 1299
Leiomyosarcoma
retroperitoneal, prognostic factors in, 359
vitaxin for, 1347 (letter)
Leptin, in cancer-associated anorexia, 629
Leukemia
acute
chronic disseminated candidiasis in, 1349
homoharringtonine for, 1591
acute lymphocytic
consanguinity and, 1
familial factors in, 1
high-risk, cranial radiotherapy for, 15
proline-directed protein kinase F_A in, chemosensitivity and, 1753
acute myelogenous
after childhood non-Hodgkin's lymphoma, 1959
investigational therapies for, 1059
liposomal daunorubicin with cytarabine for, 7
acute promyelocytic, treatment of, 1059
chronic lymphocytic
B-cell, soluble CD44 in, prognosis and, 713
cytopenia in, cyclosporin A for, 2016
incidence of, actual vs. estimated from tumor registries, 1325
chronic myelogenous
homoharringtonine for, 1591
treatment response in, survival prolongation and, 2501
gemtuzumab ozogamicin for, venoocclusive disease and, 406

lactic acidosis in, 2237
pediatric, long-term survival in, 1977
pediatric research for, informed consent for, 691
Leukocytosis, tumor-related, in lung cancer, prognosis and, 2399
Leukoplakia, loss of heterozygosity in, 2349
Limb salvage, rehabilitation in, 1013
Lipid-associated sialoprotein, in cerebrospinal fluid, brain tumors and, 856
Liposarcoma, retroperitoneal, prognostic factors in, 359
Liver. *See under* Hepatic
Lobular carcinoma in situ of breast, E-cadherin in, risk of subsequent cancer and, 738
Loss of heterozygosity, in leukoplakia, 2349
Lumpectomy, for breast cancer, in younger women, quality of life and, 1288
Lung. *See also under* Pulmonary
preneoplastic lesions of, CD44 in, 1231
toxicity of total body irradiation for, 1949
Lung cancer
ACE inhibitor protective effect for, 2462
advanced, conditional median survival in, 2211
bronchioloalveolar
DNA mismatch repair genes in, 2898
translation initiation factors 4E and 2α in, 2158
computed tomography screening for, 153
15;19 translocation and, in children, 1195
growth inhibition in, parathyroid hormone–related protein and, 1402
large cell, adjuvant chemotherapy for, 1108
MUC4 mucin in, immunogenicity of, 2148
nonsmall cell
cerebral metastasis in, after high-dose preoperative chemoradiotherapy, 160
docetaxel for, 2158
docetaxel with gemcitabine/vinorelbine for, 2391
18-fluoro-2-deoxyglucose PET staging of, in radical radiotherapy candidates, 886
gemcitabine and docetaxel for, 2902
gemcitabine and vinorelbine for, 830
γ-glutamyl cysteine synthetase in, 2911
Her-2/*neu* in, prognosis and, 1898
K-*ras* mutation, smoking and, 1525
p53 mutations in, TZT-1027 sensitivity and, 386
paclitaxel and carboplatin with/without radiotherapy for, 2142
pemetrexed disodium with cisplatin for, 595
performance status 2 in, outcome and, 2639
periostin in, 843
postoperative physician support and patient psychologic response in, 1926
prognostic factors in, 2648
psychiatric disorders in, 2609
radiotherapy for, with carboplatin/paclitaxel, 1213
RCAS1 in, prognosis and, 446
sequential combination chemotherapy for, 146
telomerase in, prognosis and, 2648
thymidine phosphorylase in, 2658
tumor-related leukocytosis in, prognosis and, 2399
tumor size–stage correlation in, 3051
vascular endothelial growth factor and interleukin-8 in, 2628
radiographic screening for, 1525
screening for, in Japan, 588
small cell
cyclophosphamide with vincristine vs. carboplatin for, 601
donor-derived, in kidney transplant recipient, 2429
metallothionein in, 836
squamous cell
eIF-4G in, 822
telomerase and hTERT mRNA in, during multistage carcinogenesis, 849
Lymphadenectomy
pelvic and aortic, in elderly, 2562
sentinel, for breast cancer, lymphedema after, 748
Lymphatic massage, for lymphedema, 980
Lymphatic vessel invasion, in esophageal cancer, prognosis and, 2228
Lymphedema
in breast cancer
risk factors for, 1783
after sentinel lymphadenectomy, 748
at 20-year follow-up, 1368
management of, 980
Lymph node(s), sentinel
in breast cancer
biopsy of
after preoperative chemotherapy, 1080
treatment implications of, 1769
micrometastases in, 1378
resection of, lymphedema after, 748
in melanoma, carbon dye mapping of, 535
in Merkel cell carcinoma, immunohistochemical analysis of, 1650
in papillary thyroid cancer, biopsy of, 2868
Lymph node metastasis
in breast cancer, sentinel node
histologic detection and clinical implications of, 1378
treatment implications of, 1769
in gastric cancer, genetic detection of, 2056
in head and neck cancer, vascular endothelial growth factor and, 556
immunohistochemically detected micrometastases, in gastric cancer, survival and, 753
inguinal, in anal cancer, management of, 77
Lymphocytes, peripheral blood, Fas antigen in, vs. in cytotoxic lymphocytes, in hepatocellular carcinoma, 2136
Lymphoma
acute lymphocytic, consanguinity and, 1
diffuse, dose-escalated CHOP chemotherapy for, 207
hepatic, combination chemotherapy for, 2023
HIV-related
vs. Hodgkin's disease, 2738
incidence trends and, 2948

infusional cyclophosphamide, doxorubicin and etoposide for, 200
increased incidence of, AIDS and, 2948
lactic acidosis in, 2237
pediatric, second malignancy after, 1959
primary effusion, apoptosis in, p53 and LANA in, 3076

M

Macrophage-colony stimulating factor, in ovarian cancer, 2837
MAGE-A4, in testicular tumors, 2778
Magnetic resonance imaging
for brain metastasis, in rhabdomyosarcoma, 121
of breast, with 3D fat suppression, 471
for occult subarachnoid space/spinal cord compression, in metastatic prostate cancer, 303
Malignant endocrine pancreatic tumors, cisplatin and etoposide for, 1101
Malignant fibrous histiocytoma, retroperitoneal, prognostic factors in, 359
Malignant melanoma
cutaneous, sentinel nodes in, carbon dye mapping of, 535
dacarbazine and its active metabolite for, 2190
metastatic
dacarbazine and its active metabolite for, 2190
vs. pigmented black neuroendocrine tumor of pancreas, 1984
tamoxifen plus decrescendo interleukin-2 for, 609
soluble human leukocyte antigen–G serum level in, 369
Malignant pleural mesothelioma
cisplatin, doxorubicin and interferon α-2b for, 650
cytokeratins 20 and 7 in, vs. in metastatic adenocarcinoma, 2727
hyaluronan in pleural fluid in, prognosis and, 1224
$p27^{kip1}$ in, prognosis and, 1245
Mammography, targeted subpopulations for, 1299
Maspin, in detection of bone marrow involvement, in breast cancer, 2030
Massage, for lymphedema, 980
Mastectomy
for ductal carcinoma in situ, vs. breast-conserving therapy, 23
lymphedema after
management of, 980
risk factors for, 1783
at 20-year follow-up, 1368
prophylactic, attitudes toward in English, French and Canadian women, 959
segmental, with radiotherapy, in elderly, 1092
in younger women, quality of life and, 1288
Matrix metalloproteinase-9, in colon vs. rectal cancer, 2680
Matrix type 1–matrix metalloproteinase, in breast cancer, monocyte chemoattractant protein-1 and, 1085
Maxillary sinus cancer, multimodality treatment of, 1495
Mediastinal teratomas, mature vs. immature, apoptosis and proliferative activity in, 1798
Mediastinal tumors, 15;19 translocation and, in children, 1195
Medicare claims data, for prostate cancer incidence and detection rates, 102
Medullary thyroid cancer. *See* Thyroid cancer
α-Melanocyte-stimulating hormone, for fatigue, 1714
Melanoma
cutaneous, sentinel nodes in, carbon dye mapping of, 535
metastatic
dacarbazine and its active metabolite for, 2190
vs. pigmented black neuroendocrine tumor of pancreas, 1984
tamoxifen plus decrescendo interleukin-2 for, 609
soluble human leukocyte antigen–G serum level in, 369
Menin, in adrenal tumors, 1393
Meningioma
calpain-dependent proteolysis of merlin in, 2662
chromosome 22 loss/gains in, tumor aggressiveness and, 377
embolized, clinicopathologic assessment and grading of, 701
oxidative stress and, 2662
rare *HRAS1* alleles and, 2920
rehabilitation for, 1029
Merkel cell carcinoma, sentinel lymph node analysis in, 1650
Merlin, calpain-dependent proteolysis of, in meningiomas, 2662
Mesothelioma
cisplatin, doxorubicin and interferon á-2b for, 650
hyaluronan in pleural fluid in, prognosis and, 1224
$p27^{kip1}$ in, prognosis and, 1245
Metabolic derangements, fatigue and, 1678, 1684
Metallothionein, in small cell lung cancer, 836
Metastasis
bone marrow
in breast cancer, maspin as marker for, 2030
occult, in breast cancer, prognosis and, 46
breast, 2259
cerebral
in lung cancer, after high-dose preoperative chemoradiotherapy, 160
in neonatal alveolar rhabdomyosarcoma, 1613
rehabilitation for, 1029
in rhabdomyosarcoma, routine brain scans for at diagnosis, 121
cutaneous, in neonatal alveolar rhabdomyosarcoma, 1613
hepatic, from gallbladder carcinoma, 340
liver, in colorectal cancer, chemotherapy for, 2746
lymph node
in breast cancer, sentinel node
histologic detection and clinical implications of, 1378
treatment implications of, 1769
in gastric cancer, genetic detection of, 2056

in head and neck cancer, vascular endothelial growth factor and, 556
immunohistochemically detected micrometastases, in gastric cancer, survival and, 753
inguinal, in anal cancer, management of, 77
in pancreatic cancer, *CBL2* and, 1122
pleural, cytokeratins 20 and 7 in, vs. in pleural mesothelioma, 2727
in sentinel nodes, in breast cancer, 1378
skeletal
in breast cancer, surgery for, 257
in prostate cancer
predictors of occult spinal cord compression in, 303
urinary calcium excretion in monitoring of, 1468
receptor activator of nuclear factor-*K*B ligand and, 460
rehabilitation and, 1020
in thyroid cancer, thyroglobulin mRNA assay for, 2273
in tongue cancer, predictors of, 1881
Methadone, intravenous, for pain, 1919
Methotrexate
for primary hepatic lymphoma, 2023
with vinblastine, for fibromatosis, 1259
2-Methoxyestradiol, capsase activation by, in gastric cancer, 500
O_6-Methylguanine–DNA methyltransferase methylation, *K-ras* and, in gastric cancer, 2760
Methylphenidate, for fatigue, 988, 1714
MGMT-methylation, *K-ras* and, in gastric cancer, 2760
MIB-1 labeling index, for brain tumors, prognosis and, 2720
Micrometastasis. *See* Metastasis
Microsatellite analysis, vs. cystoscopy, in bladder cancer follow-up, 768
Microsatellite instability
in brain tumors, rare *HRAS1* alleles and, 2920
in bronchioloalveolar cancer, 2898
in gastric carcinoma, 92
in ovarian cancer, 2829
Midgut carcinoids, cisplatin and etoposide for, 1101
Mitomycin C
for colorectal liver metastases, 2746
intraperitoneal, for peritoneal carcinomatosis, from colorectal cancer, 71
Mitoxantrone
for colorectal liver metastases, 2746
with cyclophosphamide, for breast cancer, 2508
for prostate cancer, 2065
Modafinil, for fatigue, 1714
Monoclonal antibodies
for acute myelogenous leukemia, 1059
for fatigue, 1714
Monocyte chemoattractant protein-1, in breast cancer, 1085
Mood disorders
fatigue and, 1684, 1694
in unresectable lung cancer, 2609
Motility-related protein 1, in endometrial cancer, prognosis and, 542
Motor deficits, rehabilitation for. *See* Cancer rehabilitation
Mouth. *See under* Oral
MRP1/CD9, in endometrial cancer, prognosis and, 542
MUC4 mucin, in lung cancer, immunogenicity of, 2148
Mucin, in gastric cancer, prognosis and, 1427
Mucositis, oral
chemotherapy-related, homeopathic medication (TRAUMEEL S) for, in children undergoing stem cell transplant, 684
radiation-induced, prophylactic benzydamine hydrochloride for, 875
Müllerian tumors, recurrent, 96-hour infusional topotecan and paclitaxel for, 1156
Multidrug resistance, PSC 833 for, 1577
Multiple endocrine neoplasia type 1 syndrome, adrenal proliferation in, menin and, 1393
Multiple myeloma
osteoprotegerin for, 460
receptor activator of nuclear factor-*K*B ligand in, 460
Muscle wasting, in cancer cachexia, 1669, 1684
Mutations. *See also specific genes*
frameshift, in ovarian cancer, 2829
MYCN status, in peripheral neuroblastic tumors, 2699
Myelodysplastic syndrome
high-risk, chemotherapy for, 1999
homoharringtonine for, 1591
Myeloma
osteoprotegerin for, 460
receptor activator of nuclear factor-*K*B ligand in, 460
Myelotoxicity, pathogenesis of, 2419
Mylortag
for acute myelogenous leukemia, 1059
venoocclusive disease and, 406

N

Narcotic analgesics. *See* Pain
Nasal cancer, treatment advances in, 3012
Nasopharyngeal cancer
Epstein-Barr virus Rta protein in, diagnostic utility of, 1872
15;19 translocation and, in children, 1195
18-fluoro-2-deoxyglucose PET for, vs. ^{99m}Tc tetrofosmin SPECT and CT, 434
radiotherapy for
carotid stenosis after, 2357
quality of life and, in China, 2126
staging systems for, in prediction of failure patterns, 2845
National Cancer Data Base report, on verrucous head and neck cancer, 110
National Cancer Institute, research funding for cancer-related fatigue by, 1737
National Center for Alternative and Complementary Medicine, research funding for cancer-related fatigue by, 1737

National Institute of Nursing Research, research funding for cancer-related fatigue by, 1737
National Institutes of Health, research funding for cancer-related fatigue by, 1737
Native Americans. *See also* Race/ethnicity
breast cancer hormone receptor status in, tumor characteristics and, 37
Native Hawaiians, breast cancer hormone receptor status in, tumor characteristics and, 37
Natural killers cells, Fas antigen in, in hepatocellular carcinoma, 2136
Natural T cells, Fas antigen in, in hepatocellular carcinoma, 2136
NCI-H727, for enhanced chemosensitivity and reduced toxicity, 2172
Neonatal rhabdomyosarcoma, with skin and brain metastases, 1613
Nephrectomy, radical laparoscopic, 1843
Nephroblastoma
c-*erb* B-2 in, transforming growth factor-α, and epidermal growth factor receptor in, prognosis and, 3120
laparoscopic radical nephrectomy for, 1843
Neurilemmoma, rare *HRAS1* alleles and, 2920
Neuroblastic tumors, prognostic classification for, 2451
Neuroblastoma
GD2 synthase in, 924
histopathology and MYCN status of, 2699
recurring screening-detected, in Japan, 349
Neurocognitive late effects, in childhood CNS tumor survivors, 2709
Neuroendocrine tumors
cisplatin and etoposide for, 1101
pigmented black pancreatic, 1984
pulmonary, adjuvant chemotherapy for, 1108
radioisotope-guided surgery for, 263
Neuroimaging, for brain metastasis in rhabdomyosarcoma, 121
Neuropeptide Y, in cancer-associated anorexia, 629
Neutropenia
chronic disseminated candidiasis in, 1349
febrile, in children, risk factors for bacteremia in, 909
Neutrophilic granulocyte function, irradiation and, 2444
Nicotine dependence, in unresectable lung cancer, 2609
NMP22, in bladder cancer monitoring, 2820
Nodal metastasis. *See* Metastasis
Nodules, dysplastic, as preneoplastic lesions in, in hepatocellular carcinoma, 2733
Non-Hodgkin's lymphoma. *See* Lymphoma
Nonsmall cell lung cancer. *See* Lung cancer, nonsmall cell
Nuclear β-catenin, in tumor budding, in colorectal cancer, 2539
Nuclear factor κB
in epithelial cell adhesion molecule regulation, 620
in oral squamous cell carcinoma, 3037
Nuclear matrix proteins NMP22, in bladder cancer monitoring, 2820
Nutrition
cancer-related fatigue and, 988
ovarian cancer and, 2318

O

Obesity
esophageal cancer and, 549
in younger women with breast cancer, prognosis and, 720
Occupational therapy. *See* Cancer rehabilitation
Oligodendrogliomas, hypoxia-inducible factor-1α in, prognosis and, 165
Oligonucleotide expression profiling, for candidate marker genes for hepatocellular carcinoma, 395
Oncology rehabilitation. *See* Cancer rehabilitation
Oophorectomy, prophylactic, attitudes toward in English, French and Canadian women, 959
Opioid analgesics. *See* Pain
Opportunistic infections
after bone marrow transplant, quality of life and, 3147
fatigue and, 1678, 1684
Oral cancer. *See also* Head and neck cancer
familial factors in, in Puerto Rico, 2102
HPV-positive squamous cell, radiosensitivity of, 805
leukoplakic loss of heterozygosity and, 2349
pRb2/p130 in, clinicopathologic correlates of, 2117
squamous cell, nuclear factor κB, IκB kinase α, and Akt kinase in, 3037
verrucous, National Cancer Data Base survey of, 110
Oral mucositis
chemotherapy-related, homeopathic medication (TRAUMEEL S) for, in children undergoing stem cell transplant, 684
radiation-induced, prophylactic benzydamine hydrochloride for, 875
Oropharyngeal cancer. *See also* Head and neck cancer; Oral cancer
HPV-positive squamous cell, radiosensitivity of, 805
Orthotopic urinary diversion, in women with pelvic tumors, 1864
Osseous metastasis
in breast cancer, surgery for, 257
in prostate cancer
predictors of occult spinal cord compression in, 303
urinary calcium excretion in monitoring of, 1468
receptor activator of nuclear factor-κB ligand and, 460
rehabilitation and, 1020
Osteopenia, after bone marrow transplant, pathogenesis of, 2419
Osteoporosis
after bone marrow transplant, pathogenesis of, 2419
pamidronate for, in prostate cancer treated with androgen blockade, 1444
Osteoprotegerin, for malignant bone disease, 460
Osteosarcoma
amputation for, rehabilitation for, 1013
ifosfamide with radiotherapy for, toxicity of, 1550
INK4A gene products in, 3062

limb salvage in, rehabilitation for, 1013
localized vs. metastatic, *p53* in, 2181
osteoprotegerin for, 460
pediatric, HER-2/*neu* oncogene amplification in, 677
receptor activator of nuclear factor-*K*B ligand in, 460
Ovarian cancer
96-hour infusional topotecan and paclitaxel for, 1156
antioxidants and, 2318
BRCA2 and, 787
CA-125-II in, 2837
chemotherapy for, with tumor debulking, 3585
cyclin-dependent kinase inhibitors in, cell proliferation and apoptosis and, 1177
epithelial, conservative treatment for, 2412
ezrin in, 3068
GLUT-1 in, prognosis and, 1144
hepatic metastasis in, multimodality treatment of, 578
hereditary, preventive strategies for, attitudes toward in English, French and Canadian women, 959
ifosfamide, paclitaxel and cisplatin for, 1856
loss of heterozygosity on chromosome 13q12–q14 in, 787
macrophage-colony stimulating factor in, 2837
microsatellite instability and frameshift mutations in, 2829
OVX1 in, 2837
p21 and p53 in, 781
somatostatin conjugate AN-238 for, 1168
Ovarian ependymoma, tumor imprint cytology of, 3165
Ovarian tumors. *See also* Ovarian cancer
borderline, conservative management of, infertility after, 320
germ cell, hepatic metastasis in, multimodality treatment of, 578
Ovulation induction, after conservative management of borderline ovarian tumors, 320
OVX1, in ovarian cancer, 2837
Oxidative stress, in meningiomas, 2662

P

$p14^{ARF}$, in ovarian cancer, cell proliferation and apoptosis and, 1177
$p16^{INK4a}$, in ovarian cancer, cell proliferation and apoptosis and, 1177
p21, in ovarian cancer, p53 and, 781
$p21^{WAF1/CIP1}$
in gastric cancer, 1828
in ovarian cancer, cell proliferation and apoptosis and, 1177
$p27^{kip1}$
in cervical cancer, 3005
in malignant pleural mesothelioma, prognosis and, 1245
in ovarian cancer, cell proliferation and apoptosis and, 1177
p53
apoptosis in HHV-8–associated malignancies, 3076
in gastric cancer, 1828
in localized vs. metastatic osteosarcoma, 2181
in lung cancer, TZT-1027 sensitivity and, 386
in ovarian cancer
cell proliferation and apoptosis and, 1177
p21 and, 781
in pulmonary artery sarcoma, 1237
in renal cancer, TZT-1027 sensitivity and, 386
vascular endothelial growth factor and, in pancreatic cancer, 1788
wild type, doxorubicin sensitivity and, in soft tissue sarcoma, 1556
p120 CTN, in prostate cancer, prognosis and, 2786
Pacific Islanders, breast cancer hormone receptor status in, tumor characteristics and, 37
Paclitaxel
with carboplatin, for head and neck cancer, 2334
with carboplatin and long-term continuous-infusion 5-fluorouracil, for advanced squamous cell carcinoma, 642
with cisplatin, for nonsmall cell lung cancer, performance status and, 2639
in combination therapy, for nonsmall cell lung cancer, performance status and, 2639
with gemcitabine, for bladder cancer, 2993
for inflammatory breast cancer, 1775
intraarterial polyoxyethylated castor oil–free, for squamous cell carcinoma, 2592
96-hour infusional, for müllerian tumors, 1156
for nonsmall cell lung cancer, with/without radiotherapy, 2142
for ovarian cancer, 1856
with radiotherapy, for nonsmall cell lung cancer, 1213
for renal cell carcinoma, 519
in sequential combination, for nonsmall cell lung cancer, 146
vasoactive intestinal peptide analog with, for enhanced chemosensitivity and reduced toxicity, 2172
Pain
fatigue and, 1678, 1684
fentanyl for, conversion from IV to transdermal administration of, 3056
intravenous methadone for, 1919
management of
in advanced cancer, 1049
conversion from IV to transdermal fentanyl in, 3056
Palliative care
intravenous methadone in, 1919
rehabilitation and, 1049. *See also* Cancer rehabilitation
Pamidronate, antiosteoporotic efficacy of, in prostate cancer treated with androgen blockade, 1444
Pancreas, pigmented black neuroendocrine tumor of, 1984
Pancreatic cancer
advanced, gemcitabine and cisplatin for, 569
angiogenesis in, 1788
basic fibroblast growth factor, prognosis and, 1788
BCL2 in, metastatic potential and, 1122

intratumoral microvessel density in, prognosis and, 1788
Ki-67 in, prognosis and, 1788
K-*Ras* mutation and *VEGF* in, 488
p53 in, prognosis and, 1788
thymidine phosphorylase in, prognosis and, 1788
vascular endothelial growth factor in, prognosis and, 1788
Pancreatic duct cell tumors, survivin in, 271
Pancreatic tumors, intraductal papillary-mucinous, clonality and field cancerization in, 1807
Papillary thyroid cancer. *See* Thyroid cancer
Paranasal sinus cancer
maxillary sinus, multimodality treatment of, 1495
treatment advances in, 3012
Parathyroid hormone–related protein, growth inhibition in lung tumors and, 1402
Parents, informed consent of, for pediatric research for leukemia, 691
Parotid region rhabdomyosarcoma, treatment of, 3135
Pathologic fractures, rehabilitation and, 1020
Patient-controlled analgesia, conversion from IV to transdermal fentanyl in, 3056
Patient education
on genetic testing, for *BRCA1/2* founder mutations, in Ashkenazi Jews, 932
quality of life and, in nasopharyngeal cancer, in China, 2126
Pediatric cancers. *See* Children *and specific cancers*
Pelvic lymphadenectomy, in elderly, 2562
Pelvic tumors, urethra-sparing cystectomy for, in women, 1864
Pemetrexed disodium, with cisplatin, for nonsmall cell lung cancer, 595
Pentoxifylline, for fatigue, 1714
Percutaneous ethanol injection, for hepatocellular carcinoma
prognostic factors for, 126
with/without transcatheter arterial chemoembolization, 1516
Period analysis, of leukemia survival, 1977
Periostin, in nonsmall cell lung cancer, prognosis and, 843
Peripheral blood lymphocytes, Fas antigen in, vs. in cytotoxic lymphocytes, in hepatocellular carcinoma, 2136
Peripheral neuroblastic tumors
histopathology and MYCN status of, 2699
pathologic classification of, 2451
Peritoneal carcinomatosis
from colorectal cancer, resection and intraperitoneal chemotherapy for, 71
pseudomyxoma peritonei in, vs. in disseminated peritoneal adenomucinosis, 85
P-glycoprotein antagonist PSC 833, with vinblastine, for advanced solid tumors, 1577
Pharyngeal cancer
diagnostic delays in, survival and, 2885
HPV-positive squamous cell, radiosensitivity of, 805
Pharyngolaryngeal cancer, chemotherapy for, 1504
Pheochromocytoma, radioisotope-guided surgery for, 263
Phosphoglycerate kinase, androgen receptor gene and, in prostate cancer, 2603
Physical activity
breast cancer risk and, 1638
in fatigue management, 988, 1689, 1699
Physical therapy. *See* Cancer rehabilitation
Physician support, postoperative psychologic response and, in lung cancer, 1926
Pigmented black neuroendocrine tumor of pancreas, 1984
Pleural fluid, hyaluronan in, in malignant pleural mesothelioma, prognosis and, 1224
Pleural mesothelioma
cisplatin, doxorubicin and interferon á-2b for, 650
cytokeratins 20 and 7 in, vs. in metastatic adenocarcinoma, 2727
hyaluronan in pleural fluid in, prognosis and, 1224
$p27^{kip1}$ in, prognosis and, 1245
Pleural metastasis, cytokeratins 20 and 7 in, vs. in pleural mesothelioma, 2727
Pleural perfusion, hyperthermic, chemotherapy with, 2197
Ploidy
in gastric cancer, prognosis and, 294
in renal cell carcinoma, prognosis and, 2280
Pneumatic pumps, for lymphedema, 980
Polymerase chain reaction. *See* Reverse transcriptase–polymerase chain reaction
Polyoxyethylated castor oil–free paclitaxel, intraarterial, for squamous cell carcinoma, 2592
Polyps, endometrial, risk factors for, in tamoxifen-treated breast cancer, 1151
Portal vein embolization, preoperative, in hepatocellular carcinoma, 2384
Ports, central venous, standard open-ended vs. Groshong catheter for, 1204
Positioning, for lymphedema, 980
Positron emission tomography
C-methionine, for low-grade glioma, prognosis and, 1541
18-fluoro-2-deoxyglucose
vs. ^{99m}Tc tetrofosmin SPECT and CT, in nasopharyngeal cancer, 434
for head and neck cancer, cost effectiveness of, 2341
for staging in radical radiotherapy candidates in nonsmall cell lung cancer, 886
Postirradiation sarcoma, comparative genomic hybridization of, 1993
$pp60^{c\text{-}src}$, in colorectal carcinoma, C-terminal Src kinase activity and, 61
pRb2/p130, in oral squamous cell carcinoma, clinicopathologic correlates of, 2117
Prednisone
dose-escalated, for diffuse lymphoma, 207

for fatigue, 1714
for primary hepatic lymphoma, 2023
Primary effusion lymphoma, apoptosis in, p53 and LANA in, 3076
Primary hepatic lymphoma, combination chemotherapy for, 2023
Progesterone receptor status, in breast cancer, race/ethnicity and, 37
Prognostic factors. *See specific cancers*
Proline-directed protein kinase F_A, in acute lymphoblastic leukemia, chemosensitivity and, 1753
Prostate biopsy suspicious for malignancy, predictive value of, 524
Prostate cancer
advanced, conditional median survival in, 2211
anastrozole for, 2095
androgen blockade for
mortality trends and, 2309
pamidronate after, 1444
androgen receptor gene CAG repeat polymorphism, in Australia, 941
androgen receptor gene in, short tandem repeat polymorphism linkage to, 2603
apoptosis in, capsases in priming for, 2297
aromatase inhibitors for, 2095
bone metastasis in
predictors of occult spinal cord compression in, 303
receptor activator of nuclear factor-*K*B ligand and, 460
urinary calcium excretion in monitoring of, 1468
catenin/E-cadherin in, prognosis and, 2786
diagnosis of, prostate specific glandular kallikrein 2 in, 2975
economic impact of, 2796
estrogen receptor-β inactivation in, 2076
genetic polymorphisms affecting androgen biosynthesis and, 1130
grading of, Gleason vs. WHO system for, 311
incidence and detection rates for, Medicare claims data for, 102
mitoxantrone for, 2065
predictive value of high-grade prostatic intraepithelial neoplasia and biopsy suspicious for malignancy for, 524
quality of life in, 1451
radiotherapy for
long-term results of, 2084
vs. watchful waiting, quality of life and, 3045
screening for
in African Americans, 2673
intraindividual variations in prostate specific antigen and, 777
suramin with hydrocortisone for, 2435
telomerase subunits in, 1943
3D conformal radiotherapy for, optimal dose for, 1281
Prostatectomy, radical, quality of life after, 1451
Prostate specific antigen
intraindividual variation in, screening implications of, 776
screening for, in African Americans, 2673
Prostate specific glandular kallikrein 2, diagnostic utility of, 2975
Prostatic intraepithelial neoplasia, prostate cancer risk and, 524
Prostheses, bone-anchored craniofacial, patient satisfaction with, 3045
Proteases, in breast cancer, prognosis and, 2957
Proteasomes, plasma levels of, as tumor marker, 2493
PSC 833, with vinblastine, for advanced solid tumors, 1577
Pseudomyxoma peritonei, with disseminated peritoneal adenomucinosis vs. peritoneal mucinous carcinomatosis, prognostic differences in, 85
Psychological problems
fatigue and, 1684, 1694
after lung cancer surgery, physician support and, 1926
in unresectable lung cancer, 2609
Psychosocial issues. *See also* Cancer rehabilitation
in amputation, 1013
in limb salvage, 1013
Psychostimulants, for fatigue, 1714
Puerto Rico, oral cancer in, familial factors in, 2102
Pulmonary artery sarcoma, apoptosis-related proteins, p53 and DNA fragmentation in, 1237
Pulmonary lesions, preneoplastic, CD44 in, 1231
Pulmonary toxicity
of total body irradiation, 1949
of total body irradiation for, 1949

Q

Quality of life
with bone-anchored craniofacial prostheses, 3111
after bone marrow transplant, illness intrusiveness and, 3147
patient education and, in nasopharyngeal cancer, in China, 2126
in prostate cancer, 1451
with radiotherapy vs. watchful waiting, 3045
rehabilitation and. *See* Cancer rehabilitation
in unresectable lung cancer, 2609
in younger women with breast cancer, impact of surgery and chemotherapy on, 1288

R

Race/ethnicity
breast cancer hormone receptor status in, tumor characteristics and, 37
comorbid illness and complications in hysterectomy for endometrial carcinoma and, 950
mammography recommendations and, 1299
prostate cancer and
genetic polymorphisms affecting androgen biosynthesis and, 1130

quality of life in, 1451
screening for, 2673
Radiation therapy
accelerated, vs. chemoradiotherapy, for head and neck cancer, 2856
for breast cancer
in elderly, 1092
soft tissue sarcoma after, 172
thyroid cancer after, 1411
for Castleman disease, stleman disease, 670
central lymphatic, for follicular lymphoma, hematologic recovery after, 1074
with chemotherapy
for cervical cancer, treatment response in, hemoglobin levels and, 903
for Hodgkin's disease, with large mediastinal involvement, 453
for maxillary sinus cancer, 1495
for nonsmall cell lung cancer, increased cerebral metastasis after, 160
for rectal cancer, fatigue and, 1725
cranial
in children, late neurocognitive effects of, 2709
for high-risk acute lymphoblastic leukemia, 15
for ductal carcinoma in situ, vs. mastectomy, 23
for esophageal cancer, in trimodality therapy, 1273
for esophageal/gastroesophageal junction cancer, with chemotherapy and surgery, 279
for glioma, with carmustine with/without interferon-α, 420
for head and neck cancer, hypothyroidism after, 2892
for HPV-positive oropharyngeal squamous cell carcinoma, 805
with ifosfamide, for sarcoma, toxicity of, 1550
for inguinal node metastases, in anal carcinoma, 77
for nasal and paranasal sinus cancer, 3012
for nasopharyngeal cancer
carotid stenosis after, 2357
quality of life and, in China, 2126
neutrophilic granulocyte function and, 2444
for nonsmall cell lung cancer
with carboplatin/paclitaxel, 1213
with paclitaxel and carboplatin, 2142
oral mucositis and, prophylactic benzydamine hydrochloride for, 875
for pediatric CNS tumors, medical and neurocognitive late effects of, 2709
preoperative, for rectal cancer, Stockholm II trial of, 896
for prostate cancer
grading systems and, 311
long-term results of, 2084
quality of life after, 1451
vs. watchful waiting, quality of life and, 3045
for retroperitoneal sarcoma, 359
for rhabdomyosarcoma of parotid region, 3135
sarcoma after, comparative genomic hybridization of, 1993
success of bone-anchored craniofacial prostheses and, 3045
3D conformal, optimal dose for, for prostate cancer, 1281
for thymoma, Thymoma, second malignancy and, 2406
total body, pulmonary toxicity of, 1949
for tracheobronchial tumors, massive hemoptysis after, 2623
Radical nephrectomy, laparoscopic, 1843
Radical prostatectomy, quality of life after, 1451
Radiofrequency ablation, for breast cancer, 2036
Radiographic screening, for lung cancer, 1525
Radioisotope-guided surgery, for pheochromocytoma and medullary thyroid cancer, 263
RANKL, osteoprotegerin and, 460
Rare *HRAS1* alleles, brain tumors and, 2920
RCAS1, in nonsmall cell lung cancer, prognosis and, 446
Receptor activator of nuclear factor-*KB* ligand, osteoprotegerin and, in malignant bone disease, 460
Rectal cancer. *See also* Colorectal cancer
gelatinases in, 2680
matrix metalloproteinase-9 in, 2680
preoperative chemoradiation for, fatigue and, 1725
preoperative radiotherapy for, Stockholm II trial of, 896
urethra-sparing cystectomy for, in women, 1864
Recursive partitioning analysis, in optimum dose determination, for 3D conformal radiation therapy, for prostate cancer, 1281
Rehabilitation. *See* Cancer rehabilitation
Renal cell carcinoma
advanced, paclitaxel, interferon-á, and *cis*-retinoic acid for, 519
cis-retinoic acid for, 519
DNA ploidy in, prognosis and, 2280
hepatic vein invasion by, 1836
laparoscopic radical nephrectomy for, 1843
long-term interleukin-2 and interferon-α for, 2286
metastatic, interferon-α for, 762
p53 mutations in, TZT-1027 sensitivity and, 386
serum amyloid A in, prognosis and, 1072
Renal transplant, donor-derived small cell lung cancer and, 2429
Research
cancer survivorship, tumor registries in, 1305
pediatric, for leukemia, informed consent for, 691
Resuscitation, survival after, predictors of, 1905
Retinoblastoma, histopathology of, drug resistance and, 2933
cis-Retinoic acid
for head and neck cancer, 814
for renal cell carcinoma, 519
Retroperitoneal sarcoma, prognostic factors in, 359
Reverse transcriptase–polymerase chain reaction
for bone marrow micrometastases, in breast cancer, 2030
for circulating tumor cells, in colorectal cancer, 2051
in identification of circulating tumor cells, in colorectal cancer, 1251

for lymph node micrometastases, in gastric cancer, 2056
Reverse transcriptase-polymerase chain reaction, for GD2 synthase, in neuroblastoma, 924
Rhabdomyosarcoma
brain metastases in, routine brain scans for at diagnosis, 121
neonatal, with skin and brain metastases, 1613
of parotid region, treatment of, 3135
Rta protein, Epstein-Barr virus, in nasopharyngeal cancer, diagnostic utility of, 1872
Rural women, mammography in, recommendations for, 1299

S

Sandwich chemiluminescence assay, for periostin, in nonsmall cell lung cancer, 843
Sarcoma. *See also specific type, e.g.,* Angiosarcoma
Ewing
ifosfamide with radiotherapy for, toxicity of, 1550
insulin-like growth factor type 1 and IGF binding protein-3 in, prognosis and, 2941
ifosfamide with radiotherapy for, toxicity of, 1550
osteogenic. *See* Osteosarcoma
postirradiation, comparative genomic hybridization of, 1993
pulmonary artery, apoptosis-related proteins, p53 and DNA fragmentation in, 1237
retroperitoneal, prognostic factors in, 359
soft tissue
doxorubicin sensitivity of, *p53* and, 1556
ifosfamide with radiotherapy for, toxicity of, 1550
Ki-67 proliferative index in, prognosis and, 869
after radiotherapy, for breast cancer, 172
T1 extremity, chest computed tomography in, 863
uterine, urethra-sparing cystectomy for, 1864
Schwannomas, rare *HRAS1* alleles and, 2920
Screening
for breast cancer, targeted subpopulations for, 1299
for lung cancer, 153
computed tomographic, 3051
in Japan, 588
for neuroblastoma, in Japan, 349
for occult subarachnoid space/spinal cord compression, in metastatic prostate cancer, 303
for prostate cancer
in African Americans, 2673
intraindividual variations in prostate specific antigen and, 777
Segmental mastectomy, with radiotherapy, in elderly, 1092
Seminomas, classical, MAGE-A4 in, 2778
Sensory deficits, rehabilitation for. *See* Cancer rehabilitation
Sentinel nodes
in breast cancer
biopsy of
after preoperative chemotherapy, 1080
treatment implications of, 1769
micrometastases in, 1378
resection of, lymphedema after, 748
in melanoma, carbon dye mapping of, 535
in Merkel cell carcinoma, immunohistochemical analysis of, 1650
in papillary thyroid cancer, biopsy of, 2868
Serum amyloid A, in renal cell carcinoma, prognosis and, 1072
Sexuality rehabilitation, 1008
Sézary syndrome, T-cell receptor gene analysis in, 1745
Short tandem repeat polymorphisms, linkage of to androgen receptor gene, in prostate cancer, 2603
Sialoprotein, lipid-associated, in cerebrospinal fluid, brain tumors and, 856
Skeletal metastasis
in breast cancer, surgery for, 257
in prostate cancer
predictors of occult spinal cord compression in, 303
urinary calcium excretion in monitoring of, 1468
receptor activator of nuclear factor-*K*B ligand and, 460
rehabilitation and, 1020
Skin cancer. *See also* Melanoma
basal cell, truncal, susceptibility to, 354
prevention of, likelihood of participation in, l315
Skin metastasis, in neonatal alveolar rhabdomyosarcoma, 1613
Sleep therapy, for fatigue, 988
Small cell lung cancer. *See* Lung cancer, small cell
Small intestinal carcinoids, incidence trends and risk factors for, 2204
Smoking
K-*ras* mutation and, in lung cancer, 1525
in unresectable lung cancer, 2609
Social support, postoperative psychologic response and, in lung cancer, 1926
Soft tissue sarcoma
doxorubicin sensitivity of, wild type *p53* and, 1556
ifosfamide with radiotherapy for, toxicity of, 1550
Ki-67 proliferative index in, prognosis and, 869
after radiotherapy, for breast cancer, 172
T1 extremity, chest computed tomography in, 863
Soluble Fas ligand, in bladder cancer, 287
Soluble human leukocyte antigen–G, in melanoma, 369
Somatostatin conjugate AN-238, for ovarian cancer, 1168
Speech therapy. *See* Cancer rehabilitation
Sperm extraction, testicular, with intracytoplasmic injection, for postchemotherapy azoospermia, 1632
S-phase fraction, in gastric cancer, prognosis and, 294
Spinal cord compression, MRI screening for, in metastatic prostate cancer, 303
Spinal cord tumors
pediatric, medical and neurocognitive late effects in, 2709
rehabilitation for, 1029
Sports participation, breast cancer risk and, 1638

Squamous cell carcinoma. *See also specific sites and types*
advanced, paclitaxel, carboplatin and long-term continuous-infusion 5-fluorouracil for, 642
cutaneous, likelihood of participation in preventive behaviors for, l315
of head and neck. *See* Head and neck cancer
of lung
eIF-4G in, 822
telomerase and hTERT mRNA in, during multistage carcinogenesis, 849
SST conjugate AN-238 for, Ovarian cancer, 1168
Staging
of cervical cancer, FIGO system for, 797
of colorectal cancer, 2754
epidermal growth factor receptor reactivity in, 1331
of mass-forming intrahepatic cholangiocarcinoma, 2374
of nasopharyngeal cancer, in prediction of failure patterns, 2845
of nonsmall cell lung cancer, tumor size and, 3051
of T1 extremity soft tissue sarcomas, chest computed tomography in, 863
of tonsillar cancer, 1484
Stearyl-Nle^{17}-neurotensin-VIP analog, for enhanced chemosensitivity and reduced toxicity, 2172
Stem cell transplantation
for acute myelogenous leukemia, 1059
illness intrusiveness after, 3147
osteoporosis after, pathogenesis of, 2419
pediatric, chemotherapy-induced stomatitis in, TRAUMEEL S for, 684
rehabilitation after, 998
Steroids
dose-escalated, for diffuse lymphoma, 207
for fatigue, 1714
for primary hepatic lymphoma, 2023
Stimulants, for fatigue, 1714
Stockholm II trial, of preoperative radiotherapy, for rectal cancer, 896
Stomach. *See under* Gastric
Stomatitis
chemotherapy-related, homeopathic medication (TRAUMEEL S) for, in children undergoing stem cell transplant, 684
radiation-induced, prophylactic benzydamine hydrochloride for, 875
Stromal tenascin-C, overexpression of, annexin II overexpression and, in colorectal cancer, 1419
Stromelysin-3, in breast cancer, prognosis and, 2957
Substance abuse, in unresectable lung cancer, 2609
Sun-protective behaviors, likelihood of adoption of, 1315
Suramin, with hydrocortisone, for prostate cancer, 2435
Surgery. *See also specific cancers and procedures*
for breast cancer. *See* Lumpectomy; Mastectomy
for esophageal cancer, in trimodality therapy, 1273
for hepatic metastases, from germ cell tumors, 578
for lymphedema, 980
radioisotope-guided, for pheochromocytoma and medullary thyroid cancer, 263
for skeletal metastasis, in breast cancer, 257
Survivin, in pancreatic duct cell tumors, 271

T

Tamoxifen
for breast cancer
vs. anastrozole, 2247
risk of endometrial polyps and, 1151
with decrescendo interleukin-2, for metastatic melanoma, 609
with radiotherapy, for ductal carcinoma in situ, vs. mastectomy, 23
Taxane analog BAY 59-8862, for glioma, 3085
Taxane-resistant breast cancer, capecitabine for, 1759
T-cell receptor gene analysis, in Sézary syndrome, 1745
T cells, Fas antigen in, in hepatocellular carcinoma, 2136
Technetium 99m–dimercaptosuccinic acid–guided surgery, for pheochromocytoma and medullary thyroid cancer, 263
Technetium 99m-MIBI scintigraphy, in prediction of chemotherapy response, in breast cancer, 232
Technetium 99m single photon emission computed tomography, vs. 18-fluoro-2-deoxyglucose PET, in nasopharyngeal cancer, 434
Telomerase, in squamous cell lung cancer, during multistage carcinogenesis, 849
Telomerase subunits, in prostate cancer, 1943
Teratomas, mediastinal
15;19 translocation and, in children, 1195
mature vs. immature, apoptosis and proliferative activity in, 1798
Terminal care, predictors of survival after CPR in, 1905
Testicular cancer, MAGE-A4 in, 2778
Testicular sperm extraction, with intracytoplasmic sperm injection, for postchemotherapy azoospermia, 1632
Testicular tumors, germ cell
hepatic metastasis in, multimodality treatment of, 578
in HIV infection, 1460
Testosterone replacement therapy, in sexuality rehabilitation, 1008
Thalidomide, for head and neck cancer, 2364
Thanatophoric dysplasia mutations in *FGFR3*, in bladder cancer, 2555
Thermal ablation, for breast cancer, 2036
13q12–q14 loss of heterozygosity, in ovarian cancer, 787
Thoracic tumors, 15;19 translocation and, in children, 1195
Thrombus, hepatic vein, in renal cell carcinoma, 1836
Thymidine phosphorylase
in nonsmall cell lung cancer, 2658
in pancreatic cancer, prognosis and, 1788
Thymidylate synthase, in bladder cancer, prognosis and, 510
Thymoma, second malignancy and, 2406

Thyroglobulin mRNA assay, in thyroid cancer, for detection of recurrence, 2273
Thyroid cancer
breast cancer risk in, 225
diagnosis of, karyometric parameters in, 1818
papillary
chromosomal abnormalities in, 2529
sentinel node biopsy in, 2868
after radiotherapy for breast cancer, 1411
recurrent medullary, radioisotope-guided surgery for, 263
thyroglobulin mRNA assay in, for detection of recurrence, 2273
TNM classification, pNO, number of regional nodes for, 452 (letter)
Tongue cancer
extracapsular spread of, prognosis and, 3030
metastasis in, predictors of, 1881
Tonsillar cancer
human papillomavirus DNA in, 2875
staging of, 1484
Topotecan
for acute myelogenous leukemia, 1059
with gemcitabine, for advanced tumors, 414
for myelodysplastic syndrome, 1999
96-hour infusional, for müllerian tumors, 1156
Total body irradiation. *See also* Radiation therapy
pulmonary toxicity of, 1949
Total gastrectomy, prophylactic, germline E-cadherin gene mutations as indication for, 181
Tracheobronchial cancer, endobronchial brachytherapy for, massive hemoptysis after, 2623
Transcatheter arterial chemoembolization, for hepatocellular carcinoma, with percutaneous ethanol injection, 1516
Transforming growth factor-α, in nephroblastoma, prognosis and, 3120
Transforming growth factor-β_1, in bladder cancer, prognosis and, 2985
Transforming growth factor-β_1 and receptors, in bladder cancer, prognosis and, 1475
Transfusion, allogeneic, in esophageal cancer, prognosis and, 1913
Transitional cell cancer, of bladder. *See* Bladder cancer
Translation initiation factor eIF-4G, in squamous cell lung cancer, 822
Translation initiation factors 4E and 2α, in bronchioloalveolar vs. squamous cell lung cancer, 2158
Translocation 15;19, pediatric upper respiratory tract cancer and, 1195
Transplantation
bone marrow/stem cell
for acute myelogenous leukemia, 1059
illness intrusiveness after, 3147
osteoporosis after, pathogenesis of, 2419
pediatric, chemotherapy-induced stomatitis in, TRAUMEEL S for, 684
rehabilitation after, 998
renal, donor-derived small cell lung cancer and, 2429
Troxacitabine, for acute myelogenous leukemia, 1059
TRUAMEEL S, for chemotherapy-induced stomatitis, in children undergoing stem cell transplant, 684
Tumor-associated antigen RCAS1, in nonsmall cell lung cancer, prognosis and, 446
Tumor imprint cytology, in ovarian ependymoma, 3165
Tumor markers. *See specific tumors and markers*
Tumor necrosis factor α, regulation of epithelial cell adhesion molecule by, 620
Tumor registries
in cancer survivorship research, 1305
chronic lymphocytic leukemia incidence predicted from, 1325
TZT-1027, sensitivity to, in lung/renal cancer, p53 mutations and, 386

U

Ultrasonography, of radiation-induced carotid stenosis, 2357
Upper extremity, lymphedema of. *See* Lymphedema
Upper respiratory tract cancer, 15;19 translocation and, in children, 1195
Uracil, with ftorafur and leucovorin, for head and neck cancer, 326
Urethra-sparing cystectomy
for pelvic tumors, 1864
in women, 1864
Urinary bladder cancer. *See* Bladder cancer
Urinary bladder carcinoma antigen ELISA test, for recurrence detection, 2811, 2820
Urinary diversion, orthotopic, in women with pelvic tumors, 1864
Urinary tumor markers, in bladder cancer monitoring, 2820
Urine, diagnosis of bladder cancer in, microsatellite analysis vs. cystoscopy for, 768
Urokinase, in breast cancer, prognosis and, 2957
Urticaria pigmentosa, with gastrointestinal stromal tumors, kit mutation and, 657
Uterine carcinoma. *See* Endometrial cancer
Uterine sarcoma, urethra-sparing cystectomy for, 1864

V

Vaginal cancer, urethra-sparing cystectomy for, 1864
Valspodar, with vinblastine, for advanced solid tumors, 1577
Vascular endothelial growth factor
in endometrial cancer, 2569
in esophageal cancer, 663
in head and neck cancer, nodal metastasis and, 556
inhibitors of, for acute myelogenous leukemia, 1059
interleukin-8 and, in nonsmall cell lung cancer, 2628
in pancreatic cancer, 488, 1788
Vascular endothelial growth factor/flk-1(KDR) receptor pathway, in endothelial cancer, 2569

Vasoactive intestinal peptide analog, for enhanced chemosensitivity and reduced toxicity, 2172
VEGF. See Vascular endothelial growth factor
Vena cava, inferior, renal cell carcinoma invasion of, 1836
Venoocclusive disease, Mylortag (gemtuzumab ozogamicin) and, 406
Verrucous head and neck cancer, National Cancer Data Base survey of, 110
Vinblastine
  with methotrexate, for fibromatosis, 1259
  with PSC 833 (Valspodar), for advanced solid tumors, 1577
Vincristine
  with cyclophosphamide, vs. carboplatin, for small cell lung cancer, 601
  dose-escalated, for diffuse lymphoma, 207
  for primary hepatic lymphoma, 2023
Vinorelbine
  for breast cancer, in salvage therapy, 2267
  with docetaxel, for nonsmall cell lung cancer, 2391
  for nonsmall cell lung cancer, 830
  vasoactive intestinal peptide analog with, for enhanced chemosensitivity and reduced toxicity, 2172
Vitamins, antioxidant, ovarian cancer risk and, 2318
Vitaxin, for leiomyosarcoma, 1347 (letter)
VP 16. *See* Etoposide

W

Wasting, fatigue and, 1669, 1684
Weight loss
  cytokines and, 1669, 1684
  fatigue and, 1684
WHO grading system, vs. Gleason grading system, for prostate cancer, 311
Wilms tumor, cancer incidence in family members and, 1606
Women, pelvic tumors in, urethra-sparing cystectomy for, 1864
WR-2721. *See* Amifostine

X

X-ray screening, for lung cancer, 1525

Z

Zidovudine, chemotherapy and, for testicular germ cell tumors in HIV infection, 1460

Authors' Index—Volume 92

A

Abbey, S. E., 3147
Abbruzzese, J. L., 2364
Abdalla, E. K., 332
Abe, N., 2539
Abeler, V. M., 2471
Abeloff, M. D., 2517
Abou-Rebyeh, H., 2280
Abraham, L. S., 1305
Abreo, F. W., 1888
Acker, P., 263
Ackerman, I., 23
Adachi, M., 488
Adak, S., 326
Adams, S., 263
Adelstein, D. J., 2892
Adsay, V., 569
Aebersold, D. M., 805
Ahmad, S. A., 1138
Ahn, J., 950
Ahn, M., 1943
Ahrendt, S. A., 1525
Aibe, H., 340
Aisner, J., 2065
Ajani, J. A., 279
Akazawa, K., 542
Akechi, T., 1926, 2609
Akiba, S., 188
Akiyama, F., 2965
Al-Abadi, H., 2280
Alawi, E. A., 1525
Alberg, A. J., 2109
Albertini, M. R., 2429
Aleong, J. C., 2259
Alfsen, G. C., 2471
Algazy, K., 414
Alho, O.-P., 2885
Allal, A. S., 3012
Allen, P. J., 1650
Alloisio, M., 650
Al-Mazrouei, M., 1
Alonso, C., 787
Altorki, N., 153
Amato, R. J., 1460
Amenta, P., 2065
Ames, F. C., 1092
Amrein, P. C., 326
Anastasiadis, P., 2569
Anderson, D. M., 2709
Anderson, H., 601
Anderson, J. R., 121, 3135
Anderson, P. R., 1281
Anderson, W. F., 37
Andersson, B. S., 1949
Andreoni, B., 1204
Andrews, B., 2985
Andrews, L., 440
Andrulis, I. L., 2181
Andrulli, S., 2286
Angioli, R., 1144
Antinori, A., 200
Antoun, S., 71
Aoki, T., 1788
Aquino, V. M., 909
Arance, A., 601
Arcediano, A., 2508
Ardizzoni, A., 650, 1896
Arencibia, J. M., 1168
Argüelles, R., 2829
Arima, J., 188
Arimidex Writing Committee on behalf of the Investigators Committee Members, 2247
Arlauskas, P., 569
Armin, M., 1331
Arnaldi, P., 1204
Arndt, M., 2680
Arnold, A., 595
Arora, N. K., 1288
Aruga, T., 2623
Asano, K., 2555
Ashfaq, R., 677
Asp, J., 3062
Atomi, Y., 2539
Au, G. K. H., 2845
Aubry, F., 2778
Aubry, L., 2493
Aubry, M.-C., 2898
Auclair, D., 843
Aufschnaiter, M., 1080
Austin, P. A., 2084
Ayoub, J., 830
Azaria, R., 1151
Azzarelli, A., 1259
Azzouzi, R., 1130

B

Baba, H., 542
Baba, M., 849, 1108
Babjuk, M., 1864
Bachtiary, B., 903
Bacigalupo, A., 2856
Baghdassarian, R., 2084
Bahar, A. Y., 440
Baiget, M., 787
Baker, E., 3093
Baker, K. S., 3135
Baker, M., 2391
Baker, M. N., 642
Bakke, S., 1577
Ball, D. L., 886
Ballestrero, A., 2030
Ballo, M. T., 1550
Balzarini, L., 650
Bandoh, N., 1495
Banerjee, D., 836
Banfi, A., 2419
Baorto, E. P., 909
Baquet, C. R., 950
Baratti, D., 1259
Barattini, P., 2484
Barce, J. M., 1606
Barceló, R., 2508
Barros, F., 2920
Barthier, S., 2267
Bartlett, N. L., 207
Barton, J. J., 326
Bartsch, G., 1864
Baruchel, S., 914
Bast, R. C., Jr., 2837
Bastian, R., 2334
Bates, S., 1577
Baudin, E., 1385
Bauer, C., 822
Bauer, H. C. F., 257
Bayley, A., 303
Bazan, V., 294
Beanlands, H. J., 3147
Beaudry, G., 2957
Becker, B. N., 2429
Bedrin, L., 1512
Beer, K. T., 805
Beger, H. G., 2746
Beghini, A., 657
Behm, F. G., 2237
Beilin, J., 941
Beiner, M. E., 320
Belani, C. P., 2639
Belette, F., 2158
Bell, R. S., 2181
Bellantone, R., 2273
Bellomi, M., 1204
Beltrán, C., 2435
Benassi, M. S., 3062
Benasso, M., 2856
Benavides, M., 2508

Ben-Baruch, G., 320
Bener, A., 1
Ben-Gal, Y., 684
Benjamin, R. S., 863, 1347, 1550
Benkendorf, J., 932
Benner, S., 326
Ben-Rafael, Z., 1190
Benson, R. L., 1606
Ben-Zvi, N., 684
Beppu, M., 3037
Beran, M., 7, 1999
Berchuck, A., 2837
Bergan, R., 1577
Berger, F., 453
Berián, J. M., 2435
Berkowitz, R. S., 1156
Bernath, A. M., 420
Bernheim, J., 1151
Berström, M., 1541
Berthon, P. L., 1130
Bertorelli, R., 2030
Bertucci, D., 1567
Bertulli, R., 1259
Beuzeboc, P., 1460
Beyth, Y., 1151
Bhuiyan, M. M. R., 1393
Bidoli, P., 2592
Biederman, E., 1402
Biffi, R., 1204
Billings, F. T., III, 2391
Billingsley, K. G., 1272
Bilous, M., 1769
Birch, J. M., 1967
Birner, P., 165
Bisogno, G., 2692
Blanc, M., 453
Blanchette, C., 2957
Blanco, A., 377
Blanco, A. I., 1074
Blancquaert, I. R., 959
Blaustein, A., 2158
Blend, R., 303
Blomqvist, C. P., 1992
Blot, F., 71
Blot, W. J., 2462
Blum, J. L., 1759
Boasberg, P. D., 609
Bobin, J.-Y., 77
Bodurka-Bevers, D., 2327
Bodvarsson, S., 2429
Bogdahn, U., 1936
Boige, V., 71
Boland, J. F., 395
Bolander, H., 1541
Bold, R. J., 1122
Bollschweiler, E., 549
Bombardelli, E., 3085
Bongiovanni, M., 1245
Bonichon, F., 359
Bonnay, M., 1385
Bonnefoi, K., 748
Bonneterre, J., 2247
Bonvalot, S., 359
Booser, D., 1775
Bordeleau, L., 23
Borgmann, V., 2280
Boscherini, M., 2273
Bossola, M., 2273
Bostick, P. J., 535
Botti, G., 2036
Bouaffia, F., 453
Bouchard, L. J., 959
Bouchier-Hayes, D., 2648
Bouhour, D., 1460
Bowers, B., 354
Boxen, I., 303
Boyages, J., 1769
Bradof, J. E., 2391
Brady, H. R., 2297
Branski, D., 684
Brantsing, C., 3062
Brasnu, D., 1504
Brass, N., 822
Braun, S., 46
Brawley, O. W., 37
Breitfellner, G., 1080
Brekken, R., 2569
Breneman, J. C., 121
Brennan, M. F., 869
Brenneman, D. E., 2172
Brenner, H., 1977
Breslow, N. E., 1606
Bretti, S., 650
Breuer, B., 2680
Brice, P., 453
Brisson, J., 2957
Brodeur, G. M., 2699
Broe, P., 2648
Brooks, S. E., 950
Brown, B. W., 225
Brown, H. G., 2720
Brown, L. M., 2102
Brücher, B. L. D. M., 2228
Brugarolas, A., 2435
Bruzzi, P., 650
Bryant, C., 1444
Bucana, C. D., 1138
Buchanan, G. R., 909
Buchholz, T. A., 1092
Buckley, M. F., 440
Buckner, J. C., 420
Budd, G. T., 1354
Budka, H., 165
Bui, B. N., 359
Bureau, J. P., 2493
Burgart, L. J., 181
Burgess, M. A., 1347, 1550
Burghen, G. A., 2237
Burkhardt-Hammer, T., 1977
Burlage, F. R., 3045
Burlingham, W., 2429
Burnett, L., 440
Burris, H. A., III, 642, 2142, 2391
Burt, P. A., 601
Burton, D. W., 1402
Busam, K., 1650
Bussolati, G., 1245
Buzdar, A., 1759, 2247
Buzdar, A. U., 1775, 2523
Buzio, C., 2286
Byron, K. A., 941

C

Cabanillas, F., 670, 1074, 2023
Cabot, M., 609
Cadeo, G., 2739
Cafferata, M. A., 1896
Cairns, D. P., 1967
Calabrò, F., 2993
Calcaterra, T., 3012
Calvo, E., 2435
Cam, W. R., 61
Campbell, K. A., 1984
Campos, S. M., 1156
Cancedda, R., 2419
Cancel, G. S., 1130
Canellos, G. P., 207
Cantor, S. B., 863
Cantuaria, G., 1144
Capanna, T., 2065
Capella, C., 657
Capomolla, E., 184
Cappia, S., 1245
Cardiella, M., 2065
Cardona, G., 1783
Carillo, S., 2493
Carli, M., 2692
Carminati, R., 2562
Carosi, G., 2739
Carozza, S. E., 2547
Carpentieri, S. C., 15
Carracedo, A., 2920
Carter, B. A., 30
Garter, W. B., 1354
Carton, M., 249
Casali, P. G., 1259
Casanova, M., 2692
Casari, S., 2739
Cascino, T. L., 420
Cassoni, P., 1245
Castaigne, D., 2412
Catasus, L., 2829
Cattaneo, C., 2739
Catton, C., 303

Catton, P., 303
Caturelli, E., 126
Cavanaugh, J. A., 748
Cecchetto, G., 2692
Cedermark, B., 896
Cedrone, A., 126
Cella, D. F., 1288
Cerhan, J. R., 240
Cerrotta, A. M., 2592
Chae, K. J., 2733
Champlin, R. E., 1949
Chan, C. L. W., 2126
Chan, P. T. K., 1632
Chan, S. H., 1872
Chao, T.-Y., 2927
Chapet, O., 77
Chaplen, R., 569
Chapman, B., 2999
Chen, A. Y., 225
Chen, C., 1577
Chen, G.-D., 92
Chen, J.-T., 2769
Chen, J.-Y., 92
Chen, L. B., 843
Chen, P. C.-H., 2406
Chen, P.-M., 2769
Chen, V. W., 2547
Chen, Y.-C., 2927
Chen, Y.-J., 2769
Chen, Z., 3068
Chenven, E. S., 2065
Cherian, M. G., 836
Cherlow, J. M., 2084
Cheson, B., 1591
Chetrit, A., 1190
Cheuk, R., 903
Cheung, I. Y., 924
Cheung, N. K. V., 924
Chevreau, C., 1460
Chi, C.-W., 92, 500
Chi, K.-H., 2406
Chiang, H., 2406
Chiaravalli, A., 657
Chico, I., 1577
Chicoine, M. R., 701
Chijiiwa, K., 340
Chiou, T.-J., 2769
Chiusa, L., 1245
Cho, Y.-K., 2760
Chochi, K., 2050
Chomez, P., 2778
Choudhury, A., 2334
Choyke, P., 1577
Chronowski, G. M., 670
Chu, K. C., 37
Chua, A. C. G., 3093
Chua, B., 1769
Chua, D. T. T., 2845
Chun, Y. S., 181
Ciancio, G., 1836
Cin, P. D., 1195
Ciudad, J., 377, 2811
Clark, J., 1213
Clark, J. I., 2334
Clarke, C. A., 218
Clough, K., 249
Cochan-Priollet, B., 1130
Coffey, R. N. T., 2297
Cohen, I., 1151
Cohen, R. B., 2095
Coindre, J.-M., 359
Coit, D. G., 1650
Colburn, D., 406
Colditz, G. A., 2318
Cole, J. T., 420
Colevas, A. D., 326
Colgan, T., 2999
Colin, P., 453
Collins, S., 2334
Coloby, P., 1864
Colomer, R., 2508
Colucci, G., 294
Committee for Pediatric Solid Malignant Tumors in the Kyushu Area, 349
Community Clinical Oncology Program, 2327
Conçalves, J. M., 377
Concannon, P., 479
Condron, C., 2648
Connelly, R. R., 2673
Conroy, R., 2648
Cook, S., 1156
Cooper, G. S., 102
Cooper, M. R., 207
Cordon-Cardo, C., 869
Cormier, J. N., 1550
Cormier, Y., 830
Correale, P., 1468
Corsale, S., 294
Cortes, J., 7, 787, 1999, 2016, 2435, 2501
Cortés-Funes, H., 2508
Cortino, P., 2036
Corvò, R., 2856
Cosso, M., 650
Costa, S. J., 2948
Costello, R., 326
Counts, D., 2941
Covens, A., 796, 2999
Coviello, D. A., 2030
Covino, M., 126
Cox, J. D., 670, 1074, 1949
Crabtree, W., 781
Crandon, A. J., 903
Crist, W. M., 3135
Cristofanilli, M., 1775
Crockett, S., 875
Cross, D. T., 701
Csernus, B., 1168
Cummings, B. J., 1484
Cummings, K. B., 2065
Cunningham, C. C., 1265
Curley, S. A., 2036
Cussenot, O., 1130

D

Da, J. P., 1621
Dafni, U., 856
Dahiya, R., 2076
Dahm, M., 1237
Dai, M.-S., 2927
D'Aiuto, G., 2036
Daling, J. R., 479, 720
Daly, B. T., 160
Damascelli, B., 2592
Damber, J.-E., 3111
D'Amico, F., 2720
Dancey, J., 595
D'Andrea, A., 950
Danesi, D. T., 2484
Dani, C., 650
Dardanoni, G., 294
David, C. L., 406
Davidson, B., 320
Davila, E., 2158
Davis, I. J., 1195
Deam, D. R., 941
Dean, A. J., 1745
De Backer, O., 2778
De Baud, F., 1204
DeBaun, M. R., 909
de Bruijn, H. W. A., 2837
de Buitrago, J. M. G., 2820
DeChiara, A., 2036
De Cian, F., 578
Decker, P. A., 1525
de Crevoisier, R., 2412
De Filippis, S., 184
Deftos, L. J., 1402
De Giuli, P., 1245
DeGregorio, M. W., 609
Dehari, H., 2117
de Irala, J., 2435
de Kerviler, E., 453
Delord, J. P., 2267
Delrio, P., 2036
Del Turco, M. R., 1783
Demers, R. Y., 2309
Demeure, M. J., 1525
Demidchik, E. P., 1818
Den Hollander, J. C., 3120
Denic, S., 1
DePetrillo, D., 2999

De Souza, P., 1444
Despa, S., 1999
Detterbeck, F. C., 1213
Devins, G. M., 3147
De Vries, A., 2444
de Wilde, P. C. M., 1881
Dharia, A., 2076
Diakomanolis, E., 1856
Diamond, T. H., 1444
Díaz, P., 377
Dickman, E., 1354
Di Como, C. J., 869
Diehl, S. R., 2102
Dienes, H. P., 2875
Dieras, V., 1759
Diesinger, I., 822
Dietrich, C. G., 2680
Dietrich, J., 1936
Diez, O., 787
Dileo, P., 1259
Dimopoulos, M. A., 1856
D'Incalci, M., 3085
DiPaola, R. S., 2065
Dipetrillo, T., 160
Dirx, M. J. M., 1638
Di Tolla, G., 2592
Diviné, M., 453
Dobbs, C., 2142
Doki, Y., 2056
Dominitz, J. A., 1272
Donaldson, S. S., 3135
Donohue, J. H., 181
Doody, D. R., 479, 720
Dorfman, R. F., 218
Dori, S., 1512
Dorr, A., 1265
Dosio, F., 2592
Dreznik, Z., 2172
Dries, V., 2875
Droz, J. P., 578
Droz, J.-P., 1460
Du, W., 519
Du, X., 730
Ducreux, M., 71
Dufresne, A., 15
Dulguerov, P., 3012
Dupont, W. D., 30
Dutaud, D., 2493
Duvillard, P., 2412

E

Ebihara, Y., 2399
Eccles, S. Z., 556
Eckel, H. E., 2875
Edelman, M. J., 146
Eden, O. B., 1967
Eder, M., 691
Eguchi, H., 349
Eisenhauer, E., 595
Eisinger, F. A., 959
El-Hassan, J., 2412
Elias, D., 71, 578
Elliott, M. E., 3147
Ellis, L. M., 1138
El-Naggar, A. K., 2364
Elomaa, A. I., 1992
El Otmany, A., 71
Emami, B., 2334
Emoto, K., 1419
Engler, H., 1541
Epstein, J. B., 875
Eriksson, A., 1541
Eriksson, B. K., 1101
Eriksson, C., 1101
Erland, J. B., 2142
Eskandari, T., 395
Eskandarian, S., 2181
Eskenazi, A., 2941
Espinosa, M. H., 471
Espinoza-Ferrel, T., 2084
Esteban, E., 2508
Estey, E., 7, 406
Estey, E. H., 1059, 1999
Eto, Y., 2555
Eton, D. T., 1451
Evans, D. G., 959
Evans, R., 1325
Evans, W. E., 1959
Ewer, M. S., 1905

F

Fabbri, F., 184
Fabel, K., 1936
Facchetti, F., 2739
Faderl, S., 1999
Fadiel, A., 3068
Fagotti, A., 1144
Fairfield, K. M., 2318
Famà, A., 2030
Fan, F., 1138
Fan, F. S., 2769
Fan, S. T., 136
Farish, S. J., 941
Fasan, M., 200
Fass, J., 2680
Faul, P. N., 1195
Favrel, V., 77
Fazzuoli, L., 2419
Feeley, T. W., 1905
Feig, B. W., 863, 1550
Feld, R., 836
Feldman, J. L., 748
Feldman, S. R., 1315
Felgenhauer, J. L., 1606
Feng, P., 1872
Feng, Y., 3068
Fermé, C., 453
Ferrandina, G., 1144, 2562
Ferrando, F., 2030
Ferrante, A., 2273
Ferrari, A., 1259, 2692
Ferrone, S., 369
Ferrozzi, F., 2286
Feusner, J. H., 3130
Fiaschi, A. I., 1468
Fidani, P., 2692
Fielding, R., 2126
Figg, W. D., 1577
Filiberti, R., 1896
Filiput, E., 701
Finegold, M. J., 3130
Fisch, M. J., 2095
Fischberg, D. J., 1919
Fisher, B., 595
Fisher, H. A. G., 2786
Fishman, E. K., 1984
Fitzpatrick, J. M., 2297
Fix, P., 620
Fizazi, K., 1460, 2267
Fjällskog, M.-L. H., 1101
Flaherty, L., 519
Fleischer, A. B., Jr., 1315
Fleming, J. B., 863
Fletcher, J. A., 1195
Flieder, D., 153
Florack, G., 2585
Fojo, T., 1577
Foley, D., 2648
Fontana, V., 1896
Ford, J., 1354
Formentini, A., 2746
Fossâ, S. D., 311
Fouladi, M., 914
Foulkes, W. D., 959
Fournier, P., 609
Fourquet, A., 249
Fraire, A. E., 2164
Francini, G., 1468
Fransson, P., 3111
Frasca, D., 2484
Fraser, R., 1213
Fraser-Andrews, E. A., 1745
Fraumeni, J. F., Jr., 2102
Freedman, L. S., 684
Freihofer, H. P. M., 1881
French, C. A., 1195
French Federation of Cancer Centers Sarcoma Group, 359
Fréneaux, P., 249
Fridkin, M., 2172
Fridman, M., 1354
Friedlander, M., 440
Friedman, E., 1190
Frigerio, L. F., 2592

Friis, S., 2462
Fritz, A., 37
Fritzsche, H., 1080
Frydenberg, M., 941
Fryer, A. A., 354
Fu, H.-H., 1753
Fuchs, P. G., 2875
Fujii, H., 2349
Fujii, S., 3005
Fujii, Y., 843
Fujimoto, H., 1419
Fujimoto, S., 386
Fujimura, S., 588
Fujino, S., 2148
Fujioka, S., 1788
Fujisawa, T., 849, 1108, 1798
Fujiwara, Y., 2056
Fukagawa, T., 753
Fukai, I., 843
Fukuda, K., 2578
Fukuda, T., 634
Fukui, Y., 2868
Fukushima, M., 510
Fuller, A. F., 1156
Fulton, J., 2547
Funami, Y., 663

G

Gajewski, J. L., 1949
Galimberti, V., 1378
Gallagher, M., 414
Gallagher, M. J., 875
Gamallo, C., 2829
Gamberi, G., 3062
Gammon, G., 609
Gammon, J., 914
Gandara, D. R., 146
Gandolfo, G. M., 713
Gansauge, F., 2746
Ganz, P. A., 1305
Garbagnati, F., 2592
Garcia, I., 2109
Garcia-Manero, G., 406
Garuti, A., 2030
Gasbarrini, G., 126
Gatter, K. C., 2569
Gatterbauer, B., 165
Gaumann, A., 1237
Geary, R. S., 1265
Gebbia, N., 294
Geisler, H. E., 781
Geisler, J. P., 781
Geisler, M. J., 781
Gelber, E., 2172
Gelber, R. D., 15
Gensabella, G., 2484
Georgiannos, S. N., 2259
Gerard, J.-P., 77
Gerbing, R. B., 2451, 2699
Ghanem, M. A., 3120
Giacobini, S., 2484
Giacosa, R., 2286
Giannarelli, D., 713
Giannice, R., 2562
Giantonio, B., 414
Giatromanolaki, A., 2569
Gika, D., 1856
Giles, F., 7, 406, 2016
Giles, F. J., 1999, 2501
Gill, I. S., 1843
Ginsberg, L. E., 2364
Giralt, S. A., 1949
Gires, O., 620
Glantz, M. J., 856
Glaser, S. L., 218
Glass, J., 1888
Glisson, B. S., 2364
Glover, D. J., 2517
Gobbi, G. A., 3062
Gockerman, J. P., 207
Goda, F., 2384
Goepfert, H., 225
Goh, C., 1484
Gokgoz, N., 2181
Goldbohm, R. A., 1638
Goldhirsch, A., 1204
Goldspiel, B., 1577
Goldstein, N. S., 738, 1331
Golia, S., 1864
Gomolin, H., 326
Gonella, R., 2030
Gonnelli, S., 1468
Goode, A. W., 2259
Goodin, S., 2065
Goodman, A., 1156
Goodman, M. D., 395
Goodman, P. C., 3051
Goodwin, J. S., 730
Gopal, R., 1949
Gorlova, O. Y., 1531
Gospodarowicz, M., 303
Gotlieb, W. H., 320
Goto, A., 2539
Goto, S., 2451, 2699
Gozes, I., 2172
Gradishar, W. J., 2517
Graeff, H., 2585
Gralow, J. R., 720
Granberg, D. P. K., 1101
Granoth, R., 2172
Grant, R., 914
Gras, E., 787, 2829
Gravina, A., 650
Gray, J. R., 2142
Greco, F. A., 642, 2142, 2391
Greenberg, J. S., 3030
Greenberg, M. L., 914
Greendale, G. A., 1305
Greene, F. L., 452
Greenlee, R., 2547
Greenspan, R., 2673
Greiner, R. H., 805
Grice, B., 1484
Gridley, G., 2102
Grisaru, D., 2999
Gronchi, A., 1259, 2692
Groome, P. A., 1484
Groome, P. G., 1411
Grosse-Wilde, H., 369
Groupe d'Etude des Lymphomes de l'Adulte, 453
Grzybicki, D. M., 2720
Guan, M., 1872
Guilford, P. J., 181
Guillaume, E. C., 1130
Guiraud, I., 2493
Gujral, A., 1402
Gunji, Y., 663
Günther, K., 1435
Gurney, J. G., 2709
Gustafson, D. H., 1288
Gutschow, C., 549
Gutterman, J., 1347

H

Ha, C. S., 670, 1074, 1949
Haas, J. E., 3130
Haasler, G. B., 1525
Haba, R., 2628
Hachisuga, T., 2578
Hachitanda, Y., 2451
Hacker, N. F., 2837
Hafez, G.-R., 2429
Haga, Y., 1108
Haid, A., 1080
Haie-Meder, C., 2412
Haigh, P. I., 535
Hainfellner, J. A., 165
Hainsworth, J. D., 642, 2142, 2391
Hall, S. F., 1484
Halle, J., 1213
Haller, D., 414
Halling, K. C., 2898
Halmos, G., 1168
Halperin, R., 1190
Hamilton-Dutoit, S. J., 1621
Han, S.-U., 2760
Hanaoka, J., 2148
Hancock, M. L., 1959
Handa, N., 349
Hankinson, S. E., 2318
Hanks, G. E., 1281
Hanlon, A. L., 1281
Hannen, E. J. M., 1881

Hans, S., 1504
Hantschmann, P., 46
Hara, N., 446
Hara, R., 2623
Hara, T., 349
Harabuchi, Y., 1495
Harewood, L., 941
Harms, D. O., 1977
Harrington, D., 2639
Harris, A. L., 2569
Hartman, G. H., 1888
Hartman, M., 1541
Harty, L. C., 2102
Hasegawa, T., 2965
Hastings, R. H., 1402
Hatfield, A. K., 420
Hau, P., 1936
Havrilesky, L. J., 2837
Hawkins, R. P., 1288
Hayashi, E., 2628
Hayashi, H., 663
Hayashi, T., 1495
Hayes, R. B., 2102
Heere-Ress, E., 2190
Hegarty, P. K., 2297
Heilbrun, L. K., 569
Helenius, H., 761
Helgeson, V. S., 1451
Helman, L., 2941
Hemminki, K., 2204
Heneghan, M. A., 2136
Hengster, P., 2444
Henry, L., 2493
Henschke, C., 1531
Henschke, C. I., 153
Hepp, F., 46
Herbst, R. S., 2364
Herd-Smith, A., 1783
Hermanek, P., 1435, 2754
Herndon, J. E., 3051
Herrala, A. M., 2975
Herzog, C. E., 1550
Heufelder, A. E., 460
Heyneman, L. E., 3051
Hicks, R. J., 886
Hill, A. D. K., 1650
Hill, D. A., 1613
Hiraide, H., 2050
Hirakawa, T., 2578
Hirao, S., 1419
Hirose, T., 3165
Hiroshima, K., 849, 1108, 1798
Hirota, M., 271
Hirsh, V., 830
Hisanaga, M., 488
Hjerpe, A., 1224
Ho, S.-T., 434
Ho, W.-K., 2845
Ho, Y.-J., 434
Hobart, M. G., 1843
Hobbs, C. M., 2045
Hoedemaeker, R. F., 524
Hofbauer, L. C., 460
Hoffer, F. A., 1613
Hoffman, H. T., 110
Hofmeister, C., 2334
Hogan, B., 2648
Hohenberger, W., 1435, 2754
Hollenbeak, C. S., 2341
Holm, T., 896
Holmlund, J. T., 1265
Hölscher, A. H., 549
Holst, D., 863
Holzberger, P., 2444
Honda, H., 340
Hong, C., 2648
Hong, W. K., 2364
Hongo, F., 287
Honma, K., 634
Hoos, A., 869
Hör, G., 263
Hornedo, J., 2508
Horowitz, Z., 1512
Hortobagyi, G. N., 1092, 1775, 2523
Horton, J., 1759
Horwitz, E. M., 1281
Horwood, K., 903
Hoshino, H., 849
Hruban, R. H., 1984
Hsia, J.-Y., 2769
Hsu, C.-P., 1753
Hsueh, S.-F., 1753
Hu, H., 1872
Hu, W., 2327
Huang, C., 488
Huang, C.-l., 2628
Huang, J., 172, 1411
Hudson, M. M., 1959
Hughes, R. D., 2136
Huismans, D. R., 2933
Hunt, K., 1775
Hunt, K. K., 863, 1092, 1550
Hunter, D. J., 2318
Hussain, M., 519
Hutzler, M. J., 2164
Hyrynkangas, K., 2885

I

Ibrahim, N., 1775
Ichikura, T., 2050
Ichinose, M., 2148
Idobe, Y., 1516
Igarashi, K., 61
Iglésias, J. L., 830
Iizasa, T., 849
Ikebe, T., 3037
Ikeda, N., 488
Ikenoue, T., 61
Iki, K., 488
Imachi, H., 1393
Imada, M., 1495
Imai, T., 2072
Imajoh-Ohmi, S., 2662
Imhof, S. M., 2933
Ingram, J. E., 2084
Inoue, S., 2148
Irie, H., 340
Irie, K., 1828
Iro, H., 822
Isaac, S., 77
Isaacs, C., 932
Ishida, T., 1393
Ishimura, K., 2384
Itami, J., 2623
Itoh, H., 2623
Ivaldi, C., 1245
Iwasaka, T., 2578
Iyoda, A., 1108, 1798
Izawa, T., 1807
Izuishi, K., 2384
Izumi, M., 446
Izzo, F., 2036

J

Jacobsen, M. S., 3012
Janda, M., 903
Janni, W., 46
Jansen, B., 2190
Janson, E. T., 1101
Jarolim, L., 1864
Järvinen, K., 2911
Jatoi, A., 629
Jégou, B., 2778
Jenkins, J., 1347
Jensen, R. A., 30
Jethva, R. N., 102
Ji, X. L., 1621
Jiang, K.-C., 92
Jiang, W.-W., 2349
Johansson, H., 896
Johnson, D. H., 2639
Johnson, J. L., 207
Johnson, L., 932
Johnson, L. G., 720
Johnson, R. D., 595
Johnston, J. F., 1265
Jokinen, K., 2885
Jones, P. W., 354
Joseph, M. G., 836
Joukhadar, C., 2190
Julian-Reynier, C. M., 959
Jung, Y. D., 1138
Jungehuelsing, M., 2875
Juzbasic, S., 200

K

Kaarteenaho-Wiik, R., 2911
Kaatsch, P., 1977, 3155
Kaemmerlen, P., 578
Kahn, B. A., 1305
Kajdacsy-Balla, A., 1525
Kakeji, Y., 1828
Kakudo, K., 54
Kalff, V., 886
Kallakury, B. V. S., 2786
Kalofonos, H. P., 2902
Kamada, K., 1419
Kameyama, K., 2628
Kanai, M., 3005
Kanehiro, H., 488
Kaneko, K., 271
Kaneko, T., 2662
Kang, M., 1577
Kankuri, M., 761
Kantarjian, H., 7, 406, 1999, 2016
Kantarjian, H. M., 1591, 2501
Kantor, G., 359
Kao, C.-H., 434
Karasawa, Y., 2384
Karnell, L. H., 110
Karp, D. D., 160
Kasuga, I., 2399
Katagiri, A., 2072
Katai, H., 753
Katano, H., 3076
Kato, I., 2211
Kato, N., 61
Katoh, H., 2399
Katopodis, N., 856
Kattan, M. W., 2985
Kau, S.-W., 2523
Kau, V., 2523
Kaufman, R. P., Jr., 2786
Kavanagh, J. J., 2327
Kawabata, T., 2050
Kawakami, K., 349
Kawakami, M., 1788
Kawamura, T., 634
Kawarabayashi, T., 2578
Kawasaki, H., 1516
Kay, E., 2648
Keating, A., 3147
Keating, M., 7, 2016
Kelly, C., 2648
Kelsey, A. M., 1967
Kentenich, C., 46
Kerneis, Y., 453
Kerr, B., 959
Kersley, J. H., 1444
Kestin, L. L., 738
Khatri, V. P., 471
Khaw, P., 886
Khojainova, N., 1919, 3056
Khouri, I. F., 1949
Khuri, F. R., 2364
Kiamouris, C., 1856
Kicic, A., 3093
Kieu, C., 620
Kim, H. S., 1427
Kim, I. Y., 1475, 2985
Kim, J.-H., 1475, 2985
Kim, L., 856
Kim, W. H., 1427
Kim, Y. B., 2733, 2760
Kim, Y. I., 1427
Kimmel, M., 1531
Kimura, M., 2072
Kimura, T., 2555
Kinnula, V. L., 2911
Kirby, K., 748
Kirillov, V. A., 1818
Kiriyama, M., 843
Kirkels, W. J., 768
Kirkpatrick, C. J., 1237
Kish, S. K., 1905
Kiyokawa, H., 2399
Kiyota, H., 2555
Klassen, A. C., 2109
Klee, G. G., 629
Klein, J., 914
Klein, N., 2190
Klussmann, J. P., 2875
Knuutila, Y. S., 1992
Kobayashi, M., 386
Kobayashi, S., 663, 2628
Kobayashi, Y., 1495
Koch, B. B., 110
Kocha, W., 836
Koda, M., 1516
Kodish, E. D., 691
Kogan, E., 1231
Kohama, G., 2117
Kohgo, Y., 1807
Kohlmann, W., 332
Koike, M., 1085
Koivunen, P., 2885
Koizumi, J., 153
Koller, C., 7, 2016
Koller, C. A., 1999
Kolligs, J., 2875
Komaki, R., 279
Komiyama, S., 3165
Komuro, Y., 3165
Kondo, T., 588
Konishi, I., 3005
Kontani, K., 2148
Koole, R., 1881
Kopolovic, J., 320
Koppan, M., 1168
Koren, G., 914
Kornblau, S., 406
Kornick, C., 1919
Kornick, C. A., 3056
Kornmann, M., 2746
Koscielny, S., 2220
Kosmas, C., 2902
Kosuge, T., 2374
Koukourakis, M. I., 2569
Kouroussis, C., 1856
Koutras, A., 2902
Kozuch, P., 2501
Kozuka, T., 2623
Krasne, D. L., 535
Krieger, J. N., 2603
Kriegsmann, J., 1237
Kristedja, T. S., 609
Kristensen, G. B., 2471
Kronenberg, J., 1512
Krook, J., 2639
Ku, P. K.-m., 2357
Kudelka, A. P., 2327
Kuerer, H. M., 1092
Kugaya, A., 1926
Kühl, J., 3155
Kuhn, W., 2585
Kun, L. E., 1613, 1959
Kunc, M., 2444
Kunz, D., 2692
Kupets, R., 796
Kurahashi, T., 3165
Kurman, R. J., 85
Kuroiwa, T., 340
Kurosaki, N., 349
Kuross, S. A., 420
Kurosumi, M., 2965
Kusaka, S., 2429
Kusakabe, T., 634
Kwoh, T. J., 1265
Kyasa, M. J., 1325
Kyllönen, A. P., 2975

L

Laccabue, D., 3085
Laccourreye, H., 1504
Laccourreye, O., 1504
Laframboise, S., 2999
Lahoti, S., 279
Laissue, J., 805
Lalli, A., 184
Lam, W. W.-m., 2357
Lamberti, C., 2484
Lang, A., 1080, 1556
Langer, C., 2639
Langleben, A., 830
Langley, P. G., 2136
Långström, B., 1541
Lanocita, R., 2592
Laplanche, A., 1385
Lapointe, H., 2957

Lara, P., 146
Larizza, L., 657
LaRose, I., 1943
Larramendy, M. L., 1992
Larto, M. A., 2892
Lasser, P., 71
Latil, A. G., 1130
Latteri, F., 294, 650
Latteri, M. A., 294
Lau, D. H. M., 146
Lauder, I. J., 146
Lavabre-Bertrand, T., 2493
Lavertu, P., 2892
Law, A., 160
Law, C. H. L., 332
Lawhorn, K. N., 2364
Lawless, G., 1354
Lear, J., 354
Le Cesne, A., 2267
Leder, G., 2746
Lee, H. K., 1427
Lee, H. S., 1427
Lee, M. W., 1354
Lehmann, W., 3012
Leo, E., 2592
Lepage, E., 453
Lepore, S. J., 1451
Lerman, C., 932
Lerner, S. P., 1475, 2985
Leskov, I. L., 1888
Leung, S.-f., 2357
Leung, W., 1959
Levato, D., 713
Levavi, H., 1190
Levenback, C., 2327
Leveque, F. G., 875
Levi, A. W., 1984
Levy, L., 225
Levy, T., 1190
Lhommé, C., 2412
Li, A. F.-Y., 92
Li, L., 1556
Li, L.-C., 2076
Li, P. J., 1621
Li, X., 2204
Libby, D., 153
Lickrish, G., 2999
Lilenbaum, R. C., 2158
Lilleby, W., 311
Lim, I. K., 2760
Limentani, S., 1213
Lin, C.-H., 2769
Lin, H.-L., 500
Lin, M., 1888
Lin, Y., 1213, 2065
Lindel, K., 805
Lindor, N. M., 181
Link, B. K., 1354
Link, K. H., 2746
Lionetto, R., 650, 2856
Lipton, J. H., 3147
Litchy, S., 2142
Liu, B. C.-S., 1943
Liu, D., 1872, 2628
Liu, F.-F., 1484
Liu, J.-H., 2769
Liu, K.-h., 2357
Liu, L., 2547
Liu, T.-Y., 500
Liu, W., 1138
Liu, Y., 2720
Lo, S.-S., 92
Lockhart, P. B., 875
Logothetis, C. J., 194, 1460
Logue, J., 303
Lombardi, C. P., 2273
Lombardo, M., 184
Londrc, A., 2084
Loonen, A. H., 2933
López, A., 377
Loprinzi, C. L., 629
Lorenz, M., 263
Lorigan, P., 601
Lo Russo, P. M., 1759
Loscertales, J., 2016
Lowe, V. J., 2341
Lowry, M. A., 2045
Loyer, E., 2327
Lu, J.-J., 2927
Lucani, B., 1468
Lucci, A., 535
Luini, A., 1378
Lukens, J. N., 2451, 2699
Lurkin, I., 768
Lutz, J., 1080
Lynch, P. M., 279
Lynch, W. J., 1444

M

Macaluso, M., 294
Machida, D., 1177
Mackillop, W. J., 172, 1411, 1484
Mac Manus, M. P., 886
MacNeill, K. M., 1156
Mader, R. M., 2190
Maeba, T., 2384
Maehara, Y., 542, 1828
Maeta, H., 2384
Magagnoli, G., 3062
Magalhaes, A., 1144
Mahvi, D. M., 1288
Mailliard, J. A., 420
Maíllo, A., 377
Maiorano, E., 1378
Maisonneuve, P., 1378
Maitra, A., 677
Majima, T., 2050
Makino, S., 2399
Makuuchi, H., 1251
Makuuchi, M., 2374
Malamos, N., 2902
Malone, K. E., 479, 720
Mameghan, H., 941
Mancuso, S., 1144, 2562
Mandahl, N., 1992
Manfredi, P., 1919
Manfredi, P. L., 3056
Manganelli, A., 1468
Mani, S., 1567
Mann, G. B., 753
Manni, J. J., 1881
Manning, J., 670
Mansmann, U., 2754
Marana, E., 2562
Marchianò, A., 2592
Margarino, G., 2856
Margariti, P. A., 2562
Marini, L., 2993
Marroni, P., 1896
Marsili, S., 1468
Martensson, G., 1224
Martin, C. G., 1905
Martin, F. D., 279
Martin, M., 609
Martínez-Monge, R., 2435
Martins, C., 2529
Martling, A., 896
Martyres, R. F., 941
Martz, C. H., 748
Maruyama, A., 542
Maruyama, K., 753
Masaki, T., 61, 2539
Masamune, A., 271
Massemin, B., 249
Mastorides, S., 869
Masudo, K., 340
Masuya, D., 2628
Matern, S., 2680
Mathoera, R. B., 3120
Matias-Guiu, X., 787, 2829
Matsubara, H., 663
Matsuda, K., 1251
Matsudo, T., 2072
Matsuoka, H., 2539
Matsushima, K., 1085
Matsuura, N., 2056
Mattavelli, F., 2592
Matthay, K. K., 2451, 2699
Matthews, J. P., 886
Mattke, A., 2692
Matulonis, U. A., 1156
Matz, G., 2334
Maussier, L., 2273
Mayer, E., 1237

Maynard, C., 1272
Mażzarol, G., 1378
McCauley, D. I., 153
McCay, E., 3147
McConkey, D. J., 1122
McCormick, P., 2648
McGinnis, W. L., 420
McGuinness, G., 153
McKenzie, A., 886
McLaughlin, J. K., 2462
McLaughlin, P., 1074
McLean, M., 303
McLeod, D. G., 2673
McNally, R. J. Q., 1967
McNeese, M., 1775
McTavish, F., 1288
Meadows, B., 1577
Meazza, C., 2692
Medeiros, L. J., 2023
Meese, E. U., 822
Mega, H., 2349
Mekada, E., 542
Melian, E., 2334
Mellemkjœr, L., 2462
Meluch, A. A., 642
Ménard, M., 1504
Menck, H. R., 110, 1299
Mendenhall, J. H., 1288
Menesses-Diaz, A., 1475
Meraney, A. M., 1843
Mercado, G., 2892
Meric, F., 1092
Merino, M., 1577
Merkel, S., 1435, 2754
Merlano, M., 2856
Mertens, F., 1992
Messner, H. A., 3147
Metreweli, C., 2357
Meyer, W. H., 121
Michaelis, J., 1977, 3155
Michalas, S., 1856
Middleton, M. R., 601
Miettinen, M. M. A., 1992
Miettinen, O. S., 153
Migliavacca, M., 294
Mikami, I., 1926
Mikami, M., 3165
Miki, H., 2868
Miki, T., 287, 510
Milan, I., 200
Miller, G. A., 781
Miller, J. P., 701
Millikan, R. E., 194
Mills, P. K., 1299
Milosevic, M., 303
Mini, S., 1512
Mirza, N. Q., 1092
Mitchell, W., 1213
Mitsuda, A., 1516
Miyake, M., 488
Miyamoto, S., 542
Miyauchi, A., 1393
Miyazaki, M., 1913
Miyazaki, S., 349
Miyoshi, Y., 232
Mizote, H., 349
Mizukami, Y., 1807
Mizutani, Y., 287, 510
Mo, V., 3030
Moatti, J.-P., 959
Mochizuki, H., 2050
Modig, H., 3111
Molendini, L., 3062
Molica, S., 713
Moll, A. C., 2933
Monaco, R., 1468
Monden, M., 2056
Monden, Y., 2868
Monia, B., 1265
Monobe, Y., 2451
Montagnani, A., 1468
Montie, J., 2309
Moody, T. W., 2172
Moore, M. R., 2517
Moore, S. A., 2720
Morehead, C., 748
Morello, V., 294
Moreno-Bueno, G., 2829
Mori, I., 54
Morice, P., 2412
Morignat, E., 77
Morita, T., 2623
Mornex, F., 77
Morrissey, L. H., 642, 2142
Morton, D. L., 535
Morton, R. F., 420
Moul, J. W., 2673
Moulopoulos, L. A., 1856
Mousses, S., 2181
Mukai, M., 3165
Mullen, C. A., 909
Müller, M., 2190
Mullins, C. D., 950
Muñoz, A., 2508
Münz, M., 620
Muraca, M. G., 1783
Murao, K., 1393
Murawaki, Y., 1516
Murayama, C., 1251
Murgo, A., 1591
Murphy, J., 2999
Murray, J. L., 1775
Myers, C. E., 2095
Myers, J. L., 2898
Myers, J. N., 2364, 3030

N

Nabeya, Y., 663
Nabholtz, J.-M. A., 2247
Nadasdy, T., 1984
Nadji, M., 1144
Naftolin, F., 3068
Nagasaki, A., 349
Nagel, R., 2280
Nagy, A., 1168
Naidich, D. P., 153
Naimark, D. M., 23
Naito, A., 1419
Nakagawa, A., 2451
Nakajima, K., 2623
Nakajima, Y., 488, 1419
Nakamura, M., 54
Nakamura, Y., 54
Nakanishi, Y., 446, 753
Nakano, H., 488
Nakano, T., 1926
Nakao, M., 2662
Nakashima, M., 446
Nakayama, H., 3037
Namihira, H., 1393
Nan, B., 1606
Näpänkangas, U., 2911
Nashimoto, A., 634
Nasti, G., 200
Nathan, C.-A. O., 1888
Natsume, T., 386
Navajo, J. A., 2811, 2820
Neglia, J. P., 2709
Nelson, D., 1843
Nelson, T., 2327
Nemunaitis, J., 1265
Nencioni, A., 2030
Neri, M., 1896
Nesbitt, J., 279
Neubauer, A., 460
Neuberg, D. S., 2517
Neville, A., 595
Ng, I. O. L., 136
Nguyen, N. P., 1349
Nicklin, J. L., 903
Nicolas, A., 249
Nicoló, G., 1896
Nielsen, G. L., 2462
Nigra, E., 200
Nijman, R. J. M., 3120
Nikaido, T., 3005
Nikkanen, V., 761
Nilsson, A., 1541
Nishiwaki, Y., 2609
Noda, H., 1828
Noguchi, S., 232
Nojima, D., 2076
Nomura, M., 2662
Nomura, T., 2623

Nonaka, S., 1495
Nonomura, N., 510
Noordzij, M. A., 3120
Norris, S., 2136
North, L., 2023
Novick, A. C., 1843
Nozoe, T., 1913
Numoto, S., 2868
Nunes, V. M., 2529
Nyberg, G., 3111

O

Obara, T., 1807
Oberbaum, M., 684
Öberg, K. E., 1101
Oberhuber, G., 165
Obermair, A., 903
O'Brien, S., 7, 1999, 2016, 2501
O'Brien, S. M., 1591
O-charoenrat, P., 556
Ochiai, T., 663
Odajima, T., 2117
O'Day, S. J., 609
O'Dwyer, P. J., 414
O'Fallon, J. R., 420
Ogawa, O., 287, 510
Ogi, K., 2117
Ohara-Mikami, Y., 2072
Ohashi, T., 2555
Ohga, T., 1913
Ohkubo, I., 2148
Ohtani, K., 3068
Ohwada, H., 849, 1108, 1798
Ohyashiki, K., 2399
Okabayashi, T., 2374
Okada, Y., 2056
Okamoto, K., 1516
Okamoto, M., 61
Okamura, H., 1926, 2609
Okamura, J., 349
Okano, K., 2384
Okayasu, I., 1177
Okazumi, S., 663
O'Keane, C., 2297
Okugawa, K., 542
Okuyama, T., 1926
Oliver, J., 2786
Olsen, J. H., 2462
Olson, J. M., 1606
Omata, M., 61
Omura, G. A., 207
Oncology Practice Pattern Study Working Group, 1354
Onyekwere, O., 1613
Onyenadum, A., 2902
Orfao, A., 377, 2811
Orsi, F., 1204
Osborne, B., 2023
Osterwalder, B., 1759
Ostrander, E. A., 479
O'Sullivan, B., 1484
Otero, E. B., 2102
Otto, M., 1237
Ouali, A., 2493
Owen, D., 2045
Oyama, K., 1516

P

Pääkkö, P., 2911
Pachyn, D., 2585
Paganuzzi, M., 1896
Page, D. L., 30
Page, R. D., 2023
Paggiarino, D. A., 875
Pahlplatz, M. M. M., 1881
Paidas, C. N., 3135
Paik, W. K., 2760
Pakilit, A. T., 1305
Palacios, J., 2829
Palermo, G. D., 1632
Paley, M., 2197
Pallestrini, E., 2856
Pan, C.-C., 2406
Pantel, K., 46
Pantuso, G., 294
Papadopolous, N., 1347
Papadopoulos, T., 1435, 2754
Papdimitriou, C. A., 1856
Paplevka, A. A., 1818
Pappo, A. S., 121, 1613, 3135
Paquette, E. L., 2673
Paquette, L. R., 2673
Parente, C., 2941
Parham, D. M., 3135
Park, C., 2733
Park, T. J., 2760
Park, Y. N., 2733
Parker, B. A., 207
Parl, F. F., 30
Parra, H. S., 650
Pasmantier, M., 153
Passalacqua, R., 2286
Patel, S. R., 863, 1347, 1550
Patelli, G., 2592
Patrone, F., 2030
Patz, E. F., Jr., 3051
Paul, D., 1354
Paul, S. M., 2948
Paulin, C., 77
Pautier, P., 2412
Pavone, L., 2286
Payne, D., 1484
Payne, R., 1919, 3056
Pazzaglia, L., 3062
Pehamberger, H., 2190
Peleg, M., 1512
Pellegriti, G., 1385
Pelliniemi, T.-T., 761
Pellissier, J. M., 2796
Penalver, M., 1144
Penfornis, A., 1385
Peng, C.-C., 1753
Pennacchioli, E., 1259
Penson, R. T., 1156
Pentz, R., 691
Perdelli, L., 1896
Perego, P., 3085
Perez-Atayde, A. R., 1195
Pérez-Gracia, J. L., 2508
Perides, G., 856
Perinchery, G., 2076
Perley, J. E., 2084
Perley, J. M., 2084
Perng, C.-L., 2927
Perrin, L. C., 903
Perry, A., 701
Peschina, W., 1080
Peters, M., 1368
Petersen, B. T., 181
Petersen, L., 1305
Peterson, B. A., 207
Peterson, D. E., 875
Petit, N., 1460
Petrek, J. A., 1368
Petrioli, R., 1468
Petroni, G. R., 207, 2095
Petrow, P. K., 1237
Petruzzelli, G., 2334
Pettersen, E. O., 2471
Pfister, H. J., 2875
Phan, A., 406
Philip, P. A., 569
Picci, P., 3062
Piccolo, M. S. L., 924
Piel, I., 2517
Pignataro, G., 126
Pillasch, J., 2746
Pilotti, S., 1259
Pin, N., 1613
Pingree, S., 1288
Pinover, W. H., 1281
Pintar, T., 2429
Pintos, J., 830
Pironis, B., 2941
Pisters, P. W., 279
Pisters, P. W. T., 863, 1550
Pizzocaro, G., 2993
Plager, C., 1347
Plonowski, A., 1168
Pluda, J. M., 2364
Plunkett, W. K., 194
Podestà, M., 2419
Poerio, A., 2562
Pollack, M. S., 471

Pollock, R. E., 863, 1556, 2235
Polsky, D., 869
Polyzos, A., 2902
Pompili, M., 126
Pontecorvi, A., 2273
Porter, P. L., 720
Porvari, K. S., 2975
Posner, M. R., 326
Potenzoni, D., 2286
Pouillart, P., 249
Pozzessere, D., 1468
Pozzi, S., 1204
Prat, J., 787, 2829
Pratesi, G., 3085
Price, K. J., 1905
Primavera, L. H., 1919, 3056
Princi, P., 2273
Pritchard, K. I., 23
Prodinger, A., 165
Proos, A., 440
Pruneri, G., 1378
Przywara, S., 1936
Puertas, J., 2508
Pui, C.-H., 1959, 2237
Puntoni, R., 1896
Puthawala, A. A., 2084
Putnam, J. B., 279
Pyrhönen, S., 761

Q

Quarto, R., 2419
Quintana, R. A., 1402

R

Raab, S. S., 2720
Raefsky, E. L., 2142
Ragazzini, P., 3062
Raghoebar, G. M., 3045
Raijman, I., 279
Raiz, L., 3147
Raiz, P., 691
Rajpert-De Meyts, E., 2778
Rakovitch, E., 23
Ramachandran, S., 354
Ramaswamy, A., 1231
Raney, R. B., 1550
Rantala, N., 2885
Rao, B. N., 1613
Rapaccini, G. L., 126
Rashid, A., 332, 406
Raskay, B. J., 414
Rasponi, A., 1259
Ratain, M. J., 1567
Razzouk, B., 1959
Re, A., 2739
Rea, S., 184
Read, R. R., 326
Reale, F., 2273
Rebischung, C., 1460
Rebmann, V., 369
Rebollo, J., 2435
Recchia, F., 184
Refaely, Y., 2197
Reid, B. C., 2109
Reinhold, U., 369
Reinmuth, N., 1138
Reintsema, H., 3045
Ren, E. C., 1872
Renne, G., 1378
Rennie, K. M., 2709
Rey, A., 2412
Rhys-Evans, P., 556
Ribeiro, C., 2529
Ribeiro, R. C., 1959
Ribeiro-Filho, L., 2076
Ribom, D., 1541
Richie, J. P., 1943
Rickert, C. H., 3155
Ries, L. A. G., 37
Riley, D. E., 2603
Rimm, A. A., 102
Rinaldi, D., 2142
Rinaldo, M., 2036
Riofrio, M., 2267
Rios, M. B., 2501
Rioux-Leclercq, N., 2778
Rischin, D., 886
Rivera, E., 1775
Rivera, M. P., 1213
Rivoire, M., 578
Rixe, O., 2267
Rizouvski, B., 2190
Rjosk, D., 46
Roach, J. S., 2364
Roberts, D., 3030
Robertson, C., 1204, 1864
Robertson, J. F. R., 2247
Robey, R., 1577
Robinson, R. A., 110
Robison, L. R., 2709
Rocco, I., 2030
Roche, L. M., 2948
Rodolakis, A., 1856
Rodriguez, J., 2023
Rodríguez, J., 2435
Rodriguez-Galindo, C., 1613
Roeb, E., 2680
Rokana, S., 2902
Romaguera, J. E., 2023
Romano, L., 2273
Romero, I., 15
Romestaing, P., 77
Ronnett, B. M., 85
Roobol, M., 524
Roodenburg, J. L. N., 3045
Roque, L., 2529
Roselli, M., 184
Rosen, B., 2999
Rosen, P. P., 1368
Rosenman, J. G., 1213
Rosenwaks, Z., 1632
Rosenwald, I. B., 2164
Rosner, B. A., 2318
Ross, J. S., 2786
Ross, M. I., 1092
Rossi, G., 2739
Rossi, J.-F., 2493
Rossi, S., 1468
Rössler, K., 165
Rosso, R., 650, 1896, 2856
Roth, J. A., 279
Rothwell, D. M., 1484
Rotmensz, N., 1204
Rougier, P., 71
Roversi, G., 657
Rozier, R. G., 2109
Rubnitz, J. E., 1959
Ruchlin, H. S., 2796
Rufini, V., 2273
Ruiz, B., 2547
Ruiz-Ponte, C., 2920
Russell-Jones, R., 1745
Russo, A., 294, 1783
Russo, S., 1213
Rusthoven, J., 595
Rutherford, T., 3068
Rutke, S., 2585
Rutman, O., 1759
Rutqvist, L.-E., 257
Rutqvist, L. E., 896
Ryan-Robertson, A., 932

S

Sabah, G., 1190
Sadahiro, S., 1251
Saegusa, M., 1177
Saeki, H., 1913
Sagawa, M., 588
Saggio, G., 184
Sahmoud, T., 2247
Saido, T. C., 2662
Saito, T., 2072
Saito, Y., 588
Saitoh, Y., 849
Saji, H., 1085
Saji, S., 1085
Sakaiya, N., 3165
Sakakura, C., 188
Sakamoto, A., 2539
Sakamoto, G., 2965
Sakurai, T., 54
Salisbury, E., 1769
Sallah, S., 1349

Sallan, S. E., 15
Salminen, E., 761, 886
Salvatori, M., 2273
Salvestrini, F., 1468
Samet, J. M., 2109
Samiei, F., 77
Samson, M., 2778
Sánchez-Carbayo, M., 2811, 2820
Sanchez-Cespedes, M., 1525
Sandler, A. B., 2639
Sandlund, J. T., 1959, 2237
Sandvej, K., 1621
Sangiorgi, L., 3062
Sanguineti, G., 2856
Sano, T., 61, 753
Santacroce, C., 2484
Santana, V. M., 1613
Santen, R. J., 2095
Santi, R., 2286
Santiago-Palma, J., 1919, 3056
Santini, G., 2419
Santini, V., 1591
Santmyire, B. R., 1315
Santoro, A., 650
Sanz-Rodriguez, C., 2023
Sasaki, H., 843
Sasako, M., 753
Sastre-Garau, X., 249
Sata, T., 3076
Satie, A.-P., 2778
Sato, M., 588, 1393
Sato, N., 287
Sato, Y., 3076
Satoh, A., 271
Satoh, K., 271
Savage, S. S., 1843
Savas, L., 2164
Sawada, H., 1419
Sawai, S., 2148
Sawka, C. A., 23
Sawyer, D. E., 2084
Saxton, J. P., 2892
Saya, H., 2662
Sayagués, J. M., 377
Scambia, G., 1144, 2562
Scanziani, E., 3085
Schally, A. V., 1168
Schatz, M., 2746
Scheithauer, B. W., 420
Schell, M. J., 1213
Scherf, U., 395
Schichman, S. A., 1325
Schiller, J., 2639
Schilsky, R. L., 1567
Schimmer, A. D., 3147
Schindl, M., 165
Schindlbeck, C., 46
Schlegel, P. N., 1632
Schlumberger, M., 1385
Schmalfeldt, B., 2585
Schmitt, B., 620
Schneider, D., 1190
Schnetzer, S., 2993
Schoen, P. J., 3045
Schomberg, P. J., 420
Schouten-van Meeteren, A. Y. N., 2933
Schrappe, M., 1977
Schröder, F. H., 524
Schrolnberger, C., 2190
Schubert, M. M., 875
Schuermann, M., 1231
Schultz, P. N., 1113
Schulze, K. M., 1484
Schumpelick, V., 2680
Schuyler, P., 30
Schüz, J., 3155
Schwanzelberger, B., 903
Schwartz, A. G., 2211
Schwartz, D. L., 1272
Schwartz, M. A., 2158
Schwartz, M. D., 932
Schweizer, D. K., 1843
Scott, S., 1354
Secic, M., 2892
Seeger, R. C., 2699
Sega, W., 1080
Sehdev, A. E. S., 1984
Seiden, M. V., 1156
Seigel, L., 2158
Seiki, M., 1085
Seki, S., 2050
Sekine, Y., 849
Sella, A., 2993
Sellers, T. A., 240
Sener, S. F., 748
Senie, R. T., 1368
Senzer, N. N., 875
Sera, Y., 349
Serio, G., 657
Sertoli, M. R., 2419
Sesterhenn, I. A., 2673
Severson, R. K., 2211, 2309
Sham, J. S. T., 2126, 2845
Shan, J., 2501
Shanberg, A. M., 2084
Shapira, J., 1151
Shapiro, B. L., 15
Shariat, S. F., 1475, 2985
Shaw, P., 2999
Sheaff, M., 2259
Sheehan, C. E., 2786
Shelley, W., 1411
Shen, Y., 7, 1999, 2837
Shenep, J. L., 2237
Shepherd, F. A., 595
Shi, R., 1888
Shibuya, K., 849
Shields, A. F., 569
Shih, W. J., 2065
Shimada, H., 663, 2451, 2699
Shimada, K., 2374
Shimada, M., 340
Shimadzu, M., 2965
Shimoda, T., 753
Shimosegawa, T., 271
Shin, D. M., 2364
Shiohara, S., 3005
Shiozaki, H., 2056
Shiozawa, T., 3005
Shirahama, T., 188
Shirai, T., 2349
Shirasuna, K., 3037
Shiratori, Y., 61
Shmookler, B. M., 85
Sho, M., 488
Shoshani, Y., 1512
Shumate, A., 2065
Sidransky, D., 1525
Siena, D. A., 126
Siewert, J. R., 2228
Sigounas, G., 1349
Sillos, E. M., 2237
Silverman, J. F., 2720
Silverman, L. B., 15
Silverman, S., Jr., 875
Simansky, D. A., 2197
Simon, C., 691
Simpson, J. F., 30
Singletary, E. S., 1775
Singletary, S. E., 1092
Sivridis, E., 2569
Skovlund, E., 311, 2471
Slawin, K. M., 2985
Sloan, J. A., 629
Slootweg, P. J., 1881
Smith, A., 354, 1444
Smith, J. P., 153
Smith, S., 2142
Smith, T., 1577, 1775, 2501
Smith, T. L., 194, 2523
Smits, A., 1541
Smyrk, T. C., 181
Smyth, G., 2648
Smythe, R., 279
Sneige, N., 1775
So, N. M.-c., 2357
Soares, J., 2529
Sobin, L. H., 452, 2045
Sobol, H. H., 959
Sobrido, M. J., 2920
Socinski, M. A., 1213
Soini, Y., 2911
Sollinger, H. W., 2429

Soloway, M., 1836
Sommer, H., 46
Sonoda, T., 2117
Sørensen, H. T., 2462
Spagnoli, G. C., 2778
Späthe, K., 2585
Spielmann, M., 2267
Spina, M., 200
Spitz, M. R., 225
Spreafico, C., 2592
Spunt, S. L., 121
Stack, B. C., Jr., 2341
Stadler, W. M., 1567
Staib, L., 2746
Staib-Sebler, E., 263
Stampino, C. G., 1896
Stavroyianni, N., 2902
Steele, B., 2547
Steen, P. D., 420
Stein, H. J., 2228
Stein, J., 684
Steinberg, M., 2247
Steinberg, S. M., 2941
Steinbrecher, A., 1936
Steinhart, H., 822
Steinhaus, G. D., 2364
Stelling, C., 1775
Stempak, D., 914
Stenzl, A., 1864
Stephenson, P., 2517
Stern, S. L., 535
Sternberg, C. N., 2993
Stevenson, J. P., 414
Stitt, L. W., 836
Stockholm Colorectal Cancer Study Group, 896
Stoeckle, E., 359
Stoiber, A., 903
Stojadinovic, A., 869
Stojadinvic, A., 1650
Stout, R., 601
Stram, D. O., 2451, 2699
Strange, R. C., 354
Strauchmann, N., 2190
Strobl, B., 46
Strom, E., 1775
Stronati, L., 2484
Stuppino, J. J., 471
Sturn, H., 1080
Su, L.-K., 332
Sudaryo, M. K., 3120
Sugarbaker, P. H., 85
Sugimachi, K., 1828, 1913
Sugimoto, T., 349
Sugino, T., 634
Sugita, Y., 2056
Sugiyama, M., 2539
Suita, S., 349
Summers, Y., 601
Sun, L., 2673
Sun, W., 414
Sunelaitis, E., 2746
Sung, G. T., 1843
Suou, T., 1516
Supko, J. G., 1156
Sureda, M., 2435
Susini, T., 2562
Suter, N. M., 479
Suzuki, H., 2555
Suzuki, M., 849
Suzuki, T., 634, 663, 1251
Suzuma, T., 54
Sweeney, C. J., 2639
Swisher, S., 279
Syed, A. M. N., 2084

T

Tabernero, M. D., 377
Tackels-Horne, D., 395
Taguchi, T., 232
Taicher, S., 1512
Tajima, T., 340, 1251
Tajiri, T., 349
Takagi, M., 2349
Takahara, J., 1393
Takahashi, K., 2072
Takahashi, S., 588
Takamatsu, H., 349
Takamura, Y., 232
Takayama, E., 2050
Takayama, T., 1419, 2374
Takeda, A., 663
Takeo, S., 2658
Talamini, R., 200
Tallini, G., 2273
Talmi, Y. P., 1512
Talpaz, M., 1591, 2501
Tamaki, T., 54
Tamplenizza, P., 2592
Tamura, S., 2056
Tanaka, N., 2117
Taniki, T., 2868
Tanita, T., 588
Tanno, S., 1807
Tanzarella, C., 2484
Tarbell, N. J., 15
Tarkkanen, M., 1992
Tausch, C., 1080
Taylor, G. M., 1967
Taylor, P. J., 440
Taylor, R., 1769
Taylor, S., 2523
Tazelaar, H. D., 2898
Teddy, S., 2364
Tei, C., 3165
Teot, L. A., 121
Teraoka, S. N., 479
Terasaki, H., 2965
Terrier, P., 359
Tess, J. D. T., 1259
Têtu, B., 2957
Tews, D. S., 1237
Tezuka, N., 2148
Thakar, M., 2941
Thall, P. F., 2364
Thames, H. D., 2220
Thatcher, N., 601
Theise, N., 2733
Théodore, C., 578
Theodorescu, D., 2095
Theriault, R. L., 2523
Thibodeau, S. N., 2898
Thiss, A., 1460
Thomas, D., 7, 406, 2016
Thomas, D. A., 1999
Thomas, R., 2036
Thorpe, P. E., 2569
Thürlimann, B., 2247
Thylén, A., 1224
Tibiletti, M., 657
Tichà, V., 2592
Tilgen, W., 369
Tirelli, U., 200
Tiwari, A., 2309
Tixi, L., 650
Todd, M. B., 2065
Tohma, Y., 2662
Toi, M., 1085
Tokunaga, H., 1475
Tokunaga, N., 1251
Tomasino, R. M., 294
Tomic, R., 3111
Tomita, Y., 2072
Toner, S., 2648
Toomey, D., 2648
Toretsky, J. A., 2941
Torlakovic, E., 311
Torlakovic, G., 311
Tornamira, M. V., 2508
Tortoreto, M., 3085
Toscano, M. G., 2484
Tot, T., 2727
Toyozaki, T., 1108, 1798
Tracy, D., 146
Trask, D. K., 110
Treuner, J., 2692
Tsai, S.-C., 434
Tsavaris, N., 2902
Tseng, J. E., 2364
Tsubono, Y., 588
Tsuda, H., 2965
Tsuji, I., 588
Tsuneyoshi, M., 349, 2578
Tubiolo, C., 294

Tucker, K., 440
Tucker, S. L., 1074, 1949
Tukiainen, E. J., 1992
Tumour and Angiogenesis Research Group, 2569
Turner, R. R., 535

U

Uchitomi, Y., 1926, 2609
Ueno, M., 1419
Ueno, N., 1775
Ugurel, S., 369
Ullrich, W., 1936
Ulm, K., 2585
Umehara, S., 2451, 2699
Umemura, T., 54
Ung, O., 1769
Uno, T., 2623
Urist, M. J., 869
Urrutia, M., 2811, 2820
Usuda, K., 588

V

Vaccher, E., 200
Vachon, C. M., 240
Vadiaka, M., 2902
Vaglio, A., 2286
Vaishampayan, U., 519
Vaitkevicius, V. K., 569
Valentín, V., 2508
Valerio, M. R., 294
Valero, V., 1775, 2523
Vallone, P., 2036
van den Brandt, P. A., 1638
Van den Heuvel, M. M., 3120
van der Kwast, T. H., 524, 768, 3120
van der Laak, J. A. W. M., 1881
van der Laan B. F. A. M., 3045
van der Linden, H. C., 2933
van der Valk, P., 2933
van der Zee, A. G. J., 2837
van Haaften-Day, C., 2837
van Oort, R. P., 3045
van Rhijn, B. W. G., 768
van Steenbrugge, G. J., 3120
Vaporcian, A., 279
Vargas, S. O., 1195
Varma, D. G. K., 863
Vassal, G., 1385
Vassilopoulou-Sellin, R., 225, 1113
Vaughn, D., 414
Vauthey, J.-N., 332
Vazquez, M., 153
Veeck, L. L., 1632
Veerman, A. J. P., 2933
Vega, A., 2920
Veivers, D., 1504
Veneroni, S., 3085
Venturini, M., 2419
Veronesi, U., 1378
Verschraegen, C. F., 2327
Vespro, V., 2592
Viale, G., 1378
Viberti, L., 1245
Vicini, F. A., 738
Vierkant, R. A., 240
Vihko, P. T., 2975
Villani, M. R., 126
Vincent, M., 2327
Vincent-Salomon, A., 249
Virolainen, M. J., 1992
Virudachalam, S., 1122
Vis, A. N., 524
Vissink, A., 3045
Vitale, V., 2856
Vitelli, G., 713
Vlahos, G., 1856
Vlastos, G., 1092
Vockley, J. G., 395
Vogelzang, N. J., 1567
Vogt, L. M., 395
von Euler, M., 2247
von Hundelshausen, B., 2585
Voorrips, L. E., 1638
Vos, P., 1349

W

Waber, D. P., 15
Wachs, B. H., 2084
Wada, H., 510
Waddelow, T., 406
Wagner, N. D., 207
Wakabayashi, H., 2384
Waldron, J. N., 1484
Walker, R., 1411
Walsh, G., 279
Walterhouse, D. O., 3135
Wan, J. Y., 1349
Wang, C. S., 2957
Wang, H.-J., 609
Wang, J.-J., 434
Wang, L.-S., 2406
Wang, S., 2164
Wang, W.-S., 2769
Wang, X., 2364
Wanzer, D., 677
Warde, P., 303
Warde, P. R., 1484
Wasaff, B., 1775
Watanabe, K., 634
Watanabe, T., 446
Watson, C. L., 2297
Watson, R. W. G., 2297
Weaver, D., 569
Webster, A., 2247
Wedin, R., 257
Wei, J., 2309
Wei, W. I., 2845
Weigel, B., 748
Wein, A., 1435
Weinberg, A. G., 677
Weinstein, L. J., 1943
Weinstein, M. H., 1943
Weiss, L. K., 2309
Weissenborn, S. J., 2875
Welin, S. L. V., 1101
Werner, M., 2228
Wexler, L. H., 2941
Wheeler, T. M., 1475, 2985
White, S. C., 601
Whittaker, S. J., 1745
Wicart-Poque, F., 2412
Widmark, A., 3111
Wieland, U., 2875
Wiemann, M. C., 781
Wiklund, T. A., 1992
Wilder, R. B., 670, 1074
Willett, W. C., 2318
Williams, A. J., 395
Williams, D. L., 194
Wilson, D. J., 395
Wimmel, A., 1231
Winchester, D. J., 748
Winchester, D. P., 748
Windschitl, H. E., 629, 2517
Winn, D. M., 2102, 2109
Winn-Deen, E., 2786
Winner, B., 1936
Winograd, R., 2680
Winters, J., 1444
Wirth, A., 886
Wismeth, C., 1936
Wittekind, C., 2754
Wittlin, F. N., 2158
Wolf, M., 1512
Wolfgarten, E., 549
Wollenberg, B., 620
Wolohan, L., 2297
Wolstencroft, R. A., 1745
Womer, R. B., 3135
Wong, C. M., 136
Wong, K.-s., 2357
Woolford, A. J., 1745
Wu, C.-W., 92, 500
Wu, J. K., 856
Wu, L., 85
Wu, X. C., 2547
Wunder, J. S., 2181

X

Xiong, Q., 2523
Xu, F., 2837

Y

Yamada, S., 2117
Yamada, Y., 1419
Yamakawa, T., 2868
Yamakawa, Y., 843
Yamamori, S., 2965
Yamamoto, H., 2056, 2662
Yamamoto, J., 2374
Yamasaki, S., 2374
Yamashima, T., 2662
Yamashita, H., 2623
Yamashita, J., 2662
Yamauchi, A., 2628
Yamazaki, Y., 1788
Yamori, T., 1085
Yan, H., 85
Yan, Q. H., 1621
Yan, Y., 776
Yanagawa, N., 1807
Yanagisawa, S., 1788
Yang, C.-C., 1753
Yang, H. K., 1427
Yang, P., 2898
Yang, Q., 54
Yang, S. C., 1525
Yang, S.-D., 1753
Yaniv, I., 684
Yankelevitz, D. F., 153
Yano, M., 2056
Yano, T., 2658
Yaron, M., 1190
Yasuda, S., 1251
Yasuda, T., 2056
Yellin, A., 2197
Yen, C.-C., 2769
Yen, R.-F., 434
Yen, T.-S. B., 2076
Yohsino, I., 446
Yokomise, H., 2628
Yonemura, T., 1828
Yoshida, K., 1788
Yoshida, O., 287, 510
Yoshimitsu, K., 340
Yoshimura, G., 54
Yu, C. L. M., 2126
Yu, D., 1556
Yu, Y., 2837
Yuan, Z., 102
Yue, C., 941
Yuen, H.-y., 2357
Yuen, M.-F., 2136
Yurimoto, S., 1251
Yusa, T., 1798
Yuschenko, Y. P., 1818

Z

Zaffaroni, M., 3085
Zafrani, B., 249
Zagars, G. K., 1550
Zajac, J. D., 941
Zalupski, M. M., 569
Zanna, I., 294
Zelano, G., 2273
Zelek, L., 2267
Zent, C. S., 1325
Zentgraf, R. E., 2364
Zhan, M., 1556
Zhang, W., 2673
Zhang, X. P., 1621
Zhen, W., 110
Zhou, X. G., 1621
Zhou, Y., 1959
Zhou, Z., 781
Zhu, J., 2639
Zhu, Y., 1525, 1959
Ziedler, R., 620
Ziegler, R. S., 2709
Zimmermann, G., 1080
Zou, G., 15
Zucchetti, M., 3085
Zunino, F., 2592, 3085
Zurrida, S., 1378
Zwarthoff, E. C., 768
Zyzanski, S., 691